Home · Sources

Pregnancy / prenatal

Also called prenatal care · folic acid pregnancy · first prenatal visit · gestational diabetes screening · Tdap pregnancy

Named sources. May contain inaccuracies or be incomplete. Not medical, legal, financial, or other professional advice.

Prenatal care combines regular assessment, time-sensitive prevention, explained test results and help between visits. Contact a prenatal service early, review medicines and the folic-acid plan, and ask how results and urgent concerns are handled. A screening result estimates or flags a risk; it does not settle every health question. Severe headache, vision change, chest pain, bleeding or a later drop in movement needs prompt clinical attention. The care team should tailor the plan to your history and circumstances.

What prenatal care helps you understand

Prenatal means before birth; antenatal means the same thing. Care follows both the pregnant person's health and the developing baby's health. An appointment, a preventive treatment, a screening test and an urgent assessment have different jobs. These four familiar situations show why that distinction matters.

Make early contact so the team can plan the right care

If you have a positive pregnancy test and feel well, you can still contact a prenatal service now and ask when assessment should begin. WHO describes antenatal care as continuing assessment, prevention, symptom support and education, rather than a visit reserved for illness. Medical history, previous pregnancies and current medicines can change what needs attention first. Ask how pregnancy dates will be established, because test and vaccine windows depend on how far along the pregnancy is. Tell the service about those concerns when booking, even if its first routine appointment is several weeks away. Ask what to do while waiting, who explains results and how to reach help after hours. If care starts later than expected, make contact now; missed time is a reason to prioritize remaining care, not to abandon it.

WHO recommendations on antenatal care for a positive pregnancy experience Revolutionizing prenatal care: new guidelines to transform 100-year model

Review prevention while you are waiting for the first visit

A prenatal vitamin, a vaccine and a prescription prevent different problems. Folic acid has evidence for reducing particular early brain and spinal-cord defects; it is not a promise that every pregnancy complication is prevented. Tdap helps protect an infant against whooping cough, and its pregnancy timing differs from the seasonal flu vaccine. Bring supplement ingredients and vaccination dates so the team can see what is already covered and what applies next. Do not assume that the word prenatal on a product establishes its contents, or that a previous adult vaccine dose completes every pregnancy recommendation.

Folic Acid: Facts for Clinicians ACOG 2026 Maternal Immunization Schedule

Use urgent assessment when a symptom changes

A severe headache with vision changes, chest pain, bleeding or a change in the baby's usual movement is a different question from scheduling the next routine checkup. CDC's HEAR HER campaign directs people with maternal warning signs to seek care promptly during pregnancy and up to a year afterward. A clinician may need an examination, blood-pressure measurement or fetal assessment to explain the symptom. A reassuring comment online cannot do those things. State the pregnancy stage or recent delivery and when the change began; emergency symptoms need emergency care rather than a routine appointment or an online reply.

Urgent Maternal Warning Signs and Symptoms

Ask what each test can tell you and what follows the result

If you are offered blood tests, an ultrasound or genetic testing, the important first question is what each one is checking. Screening identifies a possible problem or estimates a chance; diagnosis investigates or confirms a specific condition. An abnormal initial glucose screen can lead to a longer diagnostic test, while a genetic blood screen can lead to counseling and a different kind of confirmatory test. Ask what a positive, negative or unclear result means and who will contact you. A result is useful when its limits and follow-up are explained, not simply when it appears in a portal.

Gestational Diabetes: Screening Society for Maternal-Fetal Medicine Consult Series #74: Cell-free DNA screening for aneuploidies: Updated guidance

What the prevention findings actually mean

Prevention aims to lower a risk before a problem develops. It can be useful without being a guarantee, and its dose, timing and eligible population are part of the finding.

Cover folic acid before the early development window

The neural tube is the early structure that becomes the brain and spinal cord. When it does not close completely, neural-tube defects can result; closure occurs very early, often before pregnancy is recognized. In its 2023 evidence-based recommendation, USPSTF recommends a daily supplement containing 400–800 micrograms of folic acid for average-risk people who plan to or could become pregnant, starting at least one month before conception and continuing through the first two to three months. This reduces risk rather than eliminating it. A previous affected pregnancy, relevant family history or medicines that interfere with folic acid falls outside that standard recommendation and needs individual clinical review.

Folic Acid Supplementation to Prevent Neural Tube Defects: Preventive Medication

Read the nutrient and amount rather than relying on the brand name

Folate is vitamin B9; folic acid is a form used in supplements and fortified foods with neural-tube-prevention evidence. A label can show several folate terms, so bring the actual label if the amount is unclear. CDC explains that common MTHFR gene variants do not stop the body processing folic acid; an internet genetics result is not, by itself, a reason to replace the established prevention approach. More products do not automatically mean more protection. Review overlapping vitamins and any higher-risk history with the team rather than selecting extra doses yourself. Starting later cannot turn back an early development window, but it is still worth discussing your current nutrition and care needs.

Folic Acid: Sources and Recommended Intake MTHFR Gene Variant and Folic Acid Facts Folic Acid: Facts for Clinicians

Match each vaccine to its pregnancy purpose and timing

Maternal vaccination can protect the pregnant person and, through antibodies passed before birth, help protect an infant. CDC recommends Tdap in each pregnancy, preferably early in weeks 27–36; a prior adult dose does not replace that pregnancy dose. An inactivated or recombinant flu vaccine is recommended during the relevant season; the live nasal-spray product is different. For eligible pregnancies, maternal RSV prevention uses Abrysvo at 32 weeks 0 days through 36 weeks 6 days, seasonally—September through January in most of the continental US. Other adult RSV products are not interchangeable. Prior maternal RSV vaccination changes the later pregnancy/infant prevention plan. Ask the team to record the product, date and purpose, including any regional seasonal differences.

Guidelines for Vaccinating Pregnant Women

Use the current seasonal vaccine guidance with your care team

ACOG's 2026 maternal schedule includes COVID-19 vaccination and allows it during any trimester. CDC's newer 2026–2027 clinical considerations recommend a seasonal COVID-19 vaccine for adults and ask patients and clinicians to discuss benefits and risks. Pregnancy increases the risk of severe COVID-19 illness, which is part of that discussion. Older public pages may still describe the previous season, so the date and linked current schedule matter. The practical question is which current product and timing fit your vaccination history and health, including any prior reaction. Reading a page does not establish your individual product eligibility or dose.

ACOG 2026 Maternal Immunization Schedule Interim Clinical Considerations for Use of COVID-19 Vaccines in the United States COVID-19 Vaccination for Women Who Are Pregnant or Breastfeeding

Use alcohol prevention without making a prediction about the past

CDC has not identified a safe amount, time or type of alcohol during pregnancy. Alcohol can reach the developing fetus, and pregnancies do not all respond to exposure in the same way. The prevention recommendation is therefore to avoid alcohol, not to use a relative's healthy child as evidence for a safe allowance. If you drank before knowing you were pregnant, tell the prenatal team what occurred and continue care. That disclosure helps a clinical conversation; it does not let a website predict damage or guarantee reassurance. If avoiding alcohol is difficult, ask the clinician for support promptly rather than trying to manage the concern through shame or concealment.

About Alcohol Use During Pregnancy

Review medicines by balancing treatment and untreated illness

A medicine review includes prescriptions, nonprescription products, herbal remedies, dietary supplements and vitamins. CDC emphasizes that stopping a needed medicine can sometimes be more harmful than taking it, while some medicines can pose pregnancy risks. The decision depends on the condition being treated, the actual ingredient and dose, pregnancy timing and available evidence. A natural label supplies none of that comparison. Bring bottles or an accurate list with doses and frequency, and contact the prescribing and prenatal teams before starting or stopping treatment. Gaps in research mean uncertainty needs explanation; they do not mean every exposure is safe or every treatment should be abandoned.

Medicine and Pregnancy: An Overview

How the main prenatal assessments work

Tests answer specific questions. Understanding the question makes both reassuring and abnormal results easier to use.

Understand the glucose pathway before interpreting the number

Gestational diabetes means high blood glucose first diagnosed during pregnancy. Pregnancy can make the body less responsive to insulin, the hormone that helps move glucose out of the blood. USPSTF supports screening in people without known type 1 or type 2 diabetes at 24 weeks or later, commonly 24–28 weeks in US care. In a two-step pathway, a shorter initial glucose challenge is followed by an oral glucose-tolerance test if needed. A one-step pathway uses a diagnostic tolerance test directly. The drink, fasting instructions and number of blood samples depend on the pathway. Ask which test you are having; an abnormal screening value and a diagnosis are different pieces of information.

Gestational Diabetes: Screening

Keep blood-pressure assessment separate from aspirin prevention

Blood pressure is the force of circulating blood against artery walls. Pregnancy-related high blood pressure sometimes accompanies preeclampsia, a disorder that can also involve organ problems or other clinical findings. Monitoring helps the team identify change; aspirin is a separate preventive treatment for selected people at increased risk. USPSTF recommends clinician-prescribed low-dose aspirin after 12 weeks for eligible high-risk pregnancies, with US guidance specifying 81 mg daily. Previous preeclampsia, chronic hypertension and certain other medical histories affect eligibility. The task force's trial synthesis found fewer preeclampsia cases in high-risk groups, not universal protection. Ask whether the criteria fit your history; do not start aspirin from this article, and keep reporting symptoms even if it is prescribed.

High Blood Pressure During Pregnancy Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality: Preventive Medication

Treat genetic screening as an estimate that may need confirmation

Cell-free DNA screening, sometimes called NIPT, examines fragments of DNA circulating in the pregnant person's blood, including DNA arising mainly from the placenta. It is a sensitive screen for selected chromosome-number conditions, but it is not a direct diagnostic examination of the fetus. A positive result can be false, and a negative result cannot exclude every genetic or structural condition. SMFM's 2025 guidance, endorsed by ACOG, supports offering common-condition screening with informed counseling and the option to accept or decline testing. Ask what conditions are included and what confirmation is offered after a positive or unclear result. The result should guide a careful discussion, not be treated as an individual prognosis.

Society for Maternal-Fetal Medicine Consult Series #74: Cell-free DNA screening for aneuploidies: Updated guidance SMFM Consult Series #74 full guidance

Choose the breadth of genetic information deliberately

Chromosome conditions are not all tested with equal accuracy. Trisomy means an extra copy of a chromosome; a microdeletion is a missing small chromosome segment. The SMFM guidance treats common trisomy screening, sex-chromosome screening and rare microdeletion panels differently. Sex-chromosome screening is an opt-in choice with counseling; routine general-population microdeletion screening is not recommended. More listed conditions can mean more uncertainty and additional testing, rather than a more complete guarantee. Discuss which information you want for care and preparation, what a laboratory actually validates, and how an uncertain or unexpected result would be handled before the sample is sent.

Society for Maternal-Fetal Medicine Consult Series #74: Cell-free DNA screening for aneuploidies: Updated guidance SMFM Consult Series #74 full guidance

Connect an abnormal glucose result to continuing care

The purpose of identifying gestational diabetes is to help manage glucose and reduce selected pregnancy risks, not merely attach a label. USPSTF's evidence review found treatment benefits for outcomes including large-for-gestational-age birth and shoulder dystocia, when a baby's shoulder becomes difficult to deliver. A care plan may include nutrition support, checking glucose and medication when indicated; the details belong to your clinical team. Ask who will explain results, how monitoring is reviewed and what follow-up is planned after delivery. A diagnosis should lead to understandable support. A normal test also does not settle unrelated symptoms, blood pressure or later concerns.

Gestational Diabetes: Screening

Why care approaches can differ

These differences concern how to deliver care or interpret a test. They do not turn folic-acid prevention, urgent assessment or all recommended vaccines into optional matters of opinion.

Discuss a visit schedule that delivers the needed services

A fixed sequence of frequent office visits and a tailored combination of office and remote care are different ways of arranging services. Michigan researchers working with ACOG describe evidence supporting tailored care for average-risk pregnancies, while high-risk histories may need closer monitoring. The unresolved work includes implementation, access, technology and whether the new models serve different populations equally well. Fewer office visits must still include necessary assessments, tests, prevention and accessible between-visit contact. Ask what each contact accomplishes, what requires an in-person appointment and what would change the schedule. A preference for convenience alone cannot establish that a reduced schedule fits your pregnancy.

Revolutionizing prenatal care: new guidelines to transform 100-year model Right-sizing prenatal care

Compare glucose-testing pathways by outcomes as well as diagnoses

The one-step and two-step approaches use different thresholds, so they identify different numbers of people as having gestational diabetes. Hillier and colleagues randomized 23,792 pregnancies in two US health systems: 16.5% were diagnosed in the one-step group versus 8.5% in the two-step group, yet measured main pregnancy and infant outcomes did not significantly differ. More diagnoses did not automatically produce better measured outcomes in that trial. Adherence differed between groups, and the result does not establish that testing or treatment is useless. This is a genuine debate about thresholds, benefit and burden within screening. Ask which local protocol is used and what its result requires, rather than judging its quality by how many diagnoses it finds.

A Pragmatic Randomized Clinical Trial of Gestational Diabetes Screening

Ask whether an early glucose test is checking a different risk

USPSTF's 2021 statement found insufficient evidence to judge routine gestational-diabetes screening before 24 weeks; insufficient evidence is different from evidence that it should never occur. In the 2023 TOBOGM trial, Simmons and colleagues studied 802 women with a risk factor and already-diagnosed early gestational diabetes. Immediate treatment modestly reduced a combined infant-outcome measure, without materially changing pregnancy-related hypertension or neonatal lean body mass. That selected treatment trial does not show that every pregnant person benefits from universal early screening. Testing for previously unrecognized diabetes is also a separate clinical question. Ask why an early test is proposed for you and what action would follow its result.

Gestational Diabetes: Screening Treatment of Gestational Diabetes Mellitus Diagnosed Early in Pregnancy

Ask which diagnostic sample best answers a positive genetic screen

After some positive sex-chromosome screens, clinicians may discuss chorionic villus sampling, which samples placental tissue, or amniocentesis, which samples fluid containing fetal cells. SMFM describes continuing debate because an abnormal chromosome pattern can be present in the placenta without matching the fetus. A placental sample can provide information earlier but sometimes needs further clarification; waiting for a different sample changes the timing of information. The best choice depends on the suspected condition, ultrasound findings and laboratory method. This is a specialist counseling question, not a reason to treat the original blood screen as diagnostic. Ask what each option can confirm and what uncertainty might remain.

SMFM Consult Series #74 full guidance

How to make the care plan fit ordinary life

Care becomes more usable when its medical purpose and practical support are connected.

Read weight gain as a clinical trend rather than a personal verdict

Pregnancy weight includes changes in maternal tissues and fluid as well as the developing baby; a scale cannot separate those components. CDC's ranges, grounded mainly in National Academies guidance, depend on prepregnancy BMI and differ for singleton and twin pregnancies. BMI is a weight-to-height measure, not a complete account of nutrition or fetal growth. For example, the range for a singleton pregnancy cannot simply be reused for twins. Ask how the team interprets your trend alongside growth assessment, symptoms, intake and medical conditions, and whether nutrition support is needed. Persistent vomiting or difficulty keeping fluids down needs assessment in its own right. A chart does not diagnose the cause of a change or supply a personal meal plan.

Imagine someone compares their weight record with a chart and concludes that they must immediately change how much they eat. Before using that chart, the care team needs to know which pregnancy it describes, the starting information and the pattern over time. A singleton chart and a twin chart answer different questions; one isolated number cannot explain a change.

The person brings the record, symptoms and any difficulty eating or keeping fluids down, then asks how the team interprets them together. The useful outcome is an explained follow-up plan, including whether nutrition or other assessment is needed—not a self-assigned restriction based on a graph. This invented conversation illustrates how to use guidance as a discussion aid. It does not set a personal weight target, diagnose growth or replace prompt assessment of warning symptoms.

Weight Gain During Pregnancy Urgent Maternal Warning Signs and Symptoms

Ask how the care setting responds when needs change

Risk-appropriate care means matching medical needs to the clinicians, equipment and specialist support available. CDC's levels-of-care work explains why someone with complex disease may need a facility with resources beyond routine care. Midwifery and obstetric services can work together, but a professional title or a preferred experience does not establish a setting's emergency capability. Ask who recognizes a new complication, what specialist support is available, and where and how transfer occurs if more intensive care is needed. Maternal and newborn resources both matter. This makes the backup arrangement understandable without assuming that all pregnancies need the same facility or that all settings offer equivalent support.

CDC Levels of Care Assessment Tool (CDC LOCATe)Midwifery — University of Maryland School of Medicine

Bring a previous preterm birth into the current evidence discussion

Preterm birth means birth before 37 completed weeks. A previous spontaneous preterm birth can change assessment, but an old treatment name is not enough to identify today's options. FDA withdrew 17-OHPC in April 2023 because effectiveness for preventing recurrent spontaneous preterm birth was not established; SMFM's statement, reaffirmed 2025, discourages continued prescribing including compounded versions. Vaginal progesterone for a short cervix and cerclage—a stitch placed in the cervix for selected indications—are separate clinical questions. SMFM also describes uncertainty about progesterone in some other histories. Bring prior records and ask what your current history and cervical assessment support. Do not treat every progesterone formulation, cervical finding or pregnancy type as interchangeable.

SMFM Statement: Response to FDA withdrawal of 17-alpha hydroxyprogesterone caproate

Tell the team what makes appointments hard to use

Work hours, transportation, childcare, housing, cost, language and technology access can affect whether a care plan is workable. Peahl's care-delivery work and Howell's maternal-health programs address these as service-design and access concerns. A missed appointment is not an explanation of a person's character or a signal that care is no longer worthwhile. Tell the team what is getting in the way and ask about the appropriate practical help, interpretation, coordinated testing or different contact arrangements. If a result is unclear or a symptom concern is dismissed, ask for a plain explanation and the next available clinical assessment. Safety depends on an understandable response as well as a booked visit.

Right-sizing prenatal care New center will tackle racial disparities in maternal health Revolutionizing prenatal care: new guidelines to transform 100-year model

When to get help between appointments

Scheduled care is only one part of the plan. A new warning sign needs a response even after a reassuring test.

Get prompt clinical help for a warning sign

CDC's list includes severe or persistent headache, vision change, chest pain, trouble breathing, severe belly pain, fever, fainting, bleeding beyond spotting or fluid leakage, and movement stopping or slowing. If one occurs, seek medical care immediately and use emergency services for an emergency; do not wait for a routine visit or an online response. Once you know your baby's usual movement, a reduction matters—CDC does not give one number that is normal for every pregnancy. Discuss any bleeding with the team and seek urgent care for concerning bleeding or accompanying symptoms. These examples are not an exhaustive rule-out list. If something feels wrong or you are unsure, contact a clinician and say you are pregnant.

Urgent Maternal Warning Signs and Symptoms

Keep follow-up care in place after delivery

Pregnancy-related problems can arise after birth, so delivery does not end the need for clinical follow-up. CDC's HEAR HER guidance extends into the year after pregnancy and asks patients to tell receiving clinicians about a recent pregnancy. Keep the discharge instructions, urgent contact and handoff for ongoing conditions and medicines together. For instance, a glucose or blood-pressure concern may require follow-up beyond the birth admission; ask which clinician will review it. Stuebe's fourth trimester work treats recovery and support as a continuing care period. Postpartum means after birth, and care in that period concerns the parent's health as well as the infant's.

Urgent Maternal Warning Signs and Symptoms Alison M. Stuebe — official role and public contribution New center will tackle racial disparities in maternal health

Use this reading alongside your own prenatal care

This is a reading companion, not prenatal care, not a birth plan, and not an intimacy guide. Bleeding, severe headache, vision change, chest pain, or a later drop in fetal movement needs urgent clinical care. Do not start or stop medicines from this text. This page does not treat one pregnancy.

Named sources. Honest paraphrase of the finding. Not medical, legal, or financial advice.

Urgent Maternal Warning Signs and Symptoms Medicine and Pregnancy: An Overview

What to keep with your care record

A few useful records help the team review changes without relying on memory. They support the care relationship; they are not a home diagnosis system.

Know who will explain results and arrange follow-up

Record who ordered each test and who will explain it, especially if more than one practice is involved. Ask when results are expected and whom to contact if that date passes. A portal notification can show that a result exists without showing that its meaning or next action has been discussed. Bring unanswered questions to the next contact and ask how missed visits are rescheduled.

Revolutionizing prenatal care: new guidelines to transform 100-year model Gestational Diabetes: Screening

Keep the agreed supplement plan with the medicine list

Write the product, ingredient amount and frequency, then add any change the clinical team recommends. This helps avoid accidental overlap when someone suggests another prenatal product. Keep the purpose clear: folic acid lowers the risk of specific early structural defects; it does not treat a detected defect. Review changes rather than interpreting a different bottle as a stronger prevention plan.

Folic Acid: Sources and Recommended Intake Folic Acid Supplementation to Prevent Neural Tube Defects: Preventive Medication Medicine and Pregnancy: An Overview

Keep vaccine dates as well as names

Record the administered product and date, and bring that record when a different clinic gives care. A list saying flu or RSV does not show whether the intended seasonal or maternal dose was given. Pregnancy week, season and previous receipt can change the answer. Ask the prenatal team to identify what is complete and what still needs a scheduled discussion.

Guidelines for Vaccinating Pregnant Women ACOG 2026 Maternal Immunization Schedule

Keep urgent instructions where a support person can find them

Save the after-hours contact and intended care location alongside the warning-sign reminder. A support person can help describe the change or arrange transport, but their reassurance cannot replace an assessment. Ask what to do if the urgent number is unanswered. For an emergency, use emergency services rather than waiting indefinitely for a routine callback.

Urgent Maternal Warning Signs and Symptoms

Keep changes and questions visible between appointments

Note a new symptom, medicine change or difficulty following the plan so it can be discussed accurately. Record what the team told you and what remains unresolved, rather than collecting an unstructured pile of reassuring screenshots. Routine questions can go through the agreed channel; warning signs need the urgent route. The distinction helps a care team give the right response at the right time.

Medicine and Pregnancy: An Overview Revolutionizing prenatal care: new guidelines to transform 100-year model Urgent Maternal Warning Signs and Symptoms

Check the claim before acting on it

These answers distinguish evidence from popular reassurance. The verdict concerns the statement shown, not an individual pregnancy.

Begin the care relationship while you feel well

Claim: Early prenatal care is the field's starting step. Verdict: established. Early contact begins assessment, prevention and planning; the actual visit schedule can be tailored.

WHO recommendations on antenatal care for a positive pregnancy experience Revolutionizing prenatal care: new guidelines to transform 100-year model

Use folic acid for its specific prevention benefit

Claim: Folic acid is recommended to prevent neural-tube defects for people who could become pregnant. Verdict: established. The standard recommendation is for average-risk people; higher-risk histories need separate clinical review.

Folic Acid Supplementation to Prevent Neural Tube Defects: Preventive Medication Folic Acid: Facts for Clinicians

Use a product-specific vaccine recommendation

Claim: Vaccines are never used in pregnancy. Verdict: not what the research found. Guidance recommends specific products with pregnancy-specific timing.

Guidelines for Vaccinating Pregnant Women ACOG 2026 Maternal Immunization Schedule

Use prevention guidance instead of an anecdotal alcohol allowance

Claim: A little alcohol in pregnancy has a known safe amount. Verdict: not what the research found. CDC identifies no known safe allowance; past exposure cannot establish an individual prognosis.

About Alcohol Use During Pregnancy

Let symptoms trigger assessment rather than calendar waiting

Claim: Severe headache with vision change can wait for the next scheduled visit. Verdict: not what the research found. Those symptoms need urgent clinical assessment.

Urgent Maternal Warning Signs and Symptoms

Know the role of ordinary glucose screening

Claim: Gestational-diabetes screening is ordinary prenatal care in most US pathways. Verdict: established. USPSTF supports screening at 24 weeks or later; a testing-pathway debate does not remove that recommendation.

Gestational Diabetes: Screening A Pragmatic Randomized Clinical Trial of Gestational Diabetes Screening

Reserve aspirin for a clinical prevention decision

Claim: Low-dose aspirin is a general pregnancy vitamin. Verdict: not what the research found. It is a medicine prescribed for selected preeclampsia-risk profiles.

Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality: Preventive Medication

Make the next prenatal contact useful

One move: contact the prenatal service, or use your existing team, to confirm the care plan and how you will receive results. Bring the relevant records; use urgent care immediately if a warning sign is present.

Bring the details that let the team answer your real questions

Prepare a current medicine and supplement list with doses, product labels, vaccination dates and relevant previous pregnancy records. Ask: What needs attention before my next appointment, which tests come next, and who explains the results? Include the folic-acid question and any access difficulty. This gives the team concrete information to review instead of expecting you to know which history matters.

Medicine and Pregnancy: An Overview Folic Acid: Sources and Recommended Intake Revolutionizing prenatal care: new guidelines to transform 100-year model

Try a label-and-record check before the appointment

Read the folic-acid amount on your actual product and note other vitamins or herbal ingredients you use. Then check your vaccination record for names and dates. Bring uncertainties to the team rather than adding products or repeating doses yourself. The goal is one understandable prevention plan with individual exceptions reviewed by a clinician.

Folic Acid: Sources and Recommended Intake Medicine and Pregnancy: An Overview Guidelines for Vaccinating Pregnant Women

Try saving the follow-up and urgent routes together

Ask which number handles routine questions, which route is available after hours and where urgent symptoms should be assessed. Save the instructions where you and a support person can find them. Ask when to expect a test result and what to do if nobody explains it. The plan should cover both ordinary follow-up and unexpected change, including the handoff after delivery.

Revolutionizing prenatal care: new guidelines to transform 100-year model Urgent Maternal Warning Signs and Symptoms

References for this topic

Sources and context

WHO recommendations on antenatal care for a positive pregnancy experience ↗
id
pregnancy-prenatal--who-care — WHO recommendations on antenatal care for a positive pregnancy experience
kind
guideline
accessed at
2026-10-01
supports
Opened overview: assessment, prevention, nutrition, symptoms and person-centred antenatal care; WHO lists subsequent targeted updates.
limitations
Publication overview and update links read, not all 196 pages. Global guidance requires local adaptation.
original id
who-care
Revolutionizing prenatal care: new guidelines to transform 100-year model ↗
id
pregnancy-prenatal--prenatal-care — Revolutionizing prenatal care: new guidelines to transform 100-year model
kind
professional
accessed at
2026-10-01
supports
Opened Michigan's April 2025 account of its work with ACOG: early risk assessment; individualized services, visit schedules, telemedicine and social support.
limitations
An institutional explanation from the researchers involved; the full ACOG Clinical Consensus was unavailable for review. It does not establish one visit count for every pregnancy.
original id
prenatal-care
Folic Acid: Facts for Clinicians ↗
id
pregnancy-prenatal--folic-clinical — Folic Acid: Facts for Clinicians
kind
official
accessed at
2026-10-01
supports
Opened CDC clinical summary of folic-acid prevention and research on folate forms.
limitations
Does not establish that an arbitrary prenatal brand or higher dose is necessary.
original id
folic-clinical
ACOG 2026 Maternal Immunization Schedule ↗
id
pregnancy-prenatal--acog-vaccines — ACOG 2026 Maternal Immunization Schedule
kind
guideline
accessed at
2026-10-01
supports
Opened ACOG schedule hosted by endorsing NPWH; pages 1–2 text: Tdap, COVID-19, influenza and RSV recommendations and timing.
limitations
An ACOG schedule hosted by the endorsing organization NPWH, rather than a personal prescription.
original id
acog-vaccines
Urgent Maternal Warning Signs and Symptoms ↗
id
pregnancy-prenatal--warning-signs — Urgent Maternal Warning Signs and Symptoms
kind
official
accessed at
2026-10-01
supports
Opened CDC warning list, immediate-care direction, pregnancy/recent-pregnancy disclosure, movement change rather than universal count and one-year window.
limitations
The list is not exhaustive and cannot diagnose or rule out danger. CDC specifies bleeding beyond spotting; any bleeding should still be discussed with the care team.
original id
warning-signs
Gestational Diabetes: Screening ↗
id
pregnancy-prenatal--gdm — Gestational Diabetes: Screening
kind
guideline
accessed at
2026-10-01
supports
Opened USPSTF 2021 summary, implementation and evidence: asymptomatic screening at 24 weeks or later, often 24–28; one-/two-step pathways; earlier evidence insufficient.
limitations
Excludes previously diagnosed type 1/2 diabetes; early insufficiency is a dated evidence assessment, not a prohibition and not evaluation of symptoms.
original id
gdm
Society for Maternal-Fetal Medicine Consult Series #74: Cell-free DNA screening for aneuploidies: Updated guidance ↗
id
pregnancy-prenatal--genetic-screening — Society for Maternal-Fetal Medicine Consult Series #74: Cell-free DNA screening for aneuploidies: Updated guidance
kind
guideline
accessed at
2026-10-01
supports
Opened SMFM 2025 summary endorsed by ACOG: common aneuploidy screening, informed accept/decline choice, opt-in sex-chromosome screening and no routine microdeletion screening.
limitations
Screening does not diagnose; recommendation varies by target condition, pregnancy type and test method.
original id
genetic-screening
Folic Acid Supplementation to Prevent Neural Tube Defects: Preventive Medication ↗
id
pregnancy-prenatal--folic-acid — Folic Acid Supplementation to Prevent Neural Tube Defects: Preventive Medication
kind
guideline
accessed at
2026-10-01
supports
2023 USPSTF average-risk recommendation, 400–800 mcg daily, preconception timing, early neural-tube closure, exclusions for very-high-risk histories.
limitations
Prevention reduces risk; does not guarantee outcome or treat an established defect; higher-risk dosing requires individual care.
original id
folic-acid
Folic Acid: Sources and Recommended Intake ↗
id
pregnancy-prenatal--folic-label — Folic Acid: Sources and Recommended Intake
kind
official
accessed at
2026-10-01
supports
Opened CDC intake guidance and supplement/food distinction; actual folic-acid amount matters.
limitations
General public guidance, not personalized total nutrient requirements or a product endorsement.
original id
folic-label
MTHFR Gene Variant and Folic Acid Facts ↗
id
pregnancy-prenatal--mthfr — MTHFR Gene Variant and Folic Acid Facts
kind
official
accessed at
2026-10-01
supports
Opened CDC explanation that common MTHFR variants do not prevent folic-acid processing and folic acid has neural-tube-prevention evidence.
limitations
Common variants are different from rare metabolic disorders; not a personalized genetics assessment.
original id
mthfr
Guidelines for Vaccinating Pregnant Women ↗
id
pregnancy-prenatal--vaccines — Guidelines for Vaccinating Pregnant Women
kind
guideline
accessed at
2026-10-01
supports
Opened product/timing table and sections: Tdap each pregnancy, seasonal IIV/RIV, maternal Abrysvo weeks 32–36 and seasonal eligibility, prior maternal RSV receipt.
limitations
Page's COVID table is incomplete and linked to later guidance. Maternal RSV rules differ from other adult RSV products; local seasonality matters.
original id
vaccines
Interim Clinical Considerations for Use of COVID-19 Vaccines in the United States ↗
id
pregnancy-prenatal--covid-current — Interim Clinical Considerations for Use of COVID-19 Vaccines in the United States
kind
guideline
accessed at
2026-10-01
supports
Opened September 23, 2026 clinical page: 2026–2027 adult recommendation, current regulatory information and individualized benefits/risks discussion.
limitations
Landing-page summary read; no brand, dose or regulatory eligibility inferred. A stale 'last updated 2025' subheading conflicts with 2026 page metadata.
original id
covid-current
COVID-19 Vaccination for Women Who Are Pregnant or Breastfeeding ↗
id
pregnancy-prenatal--covid-pregnancy — COVID-19 Vaccination for Women Who Are Pregnant or Breastfeeding
kind
official
accessed at
2026-10-01
supports
Opened pregnancy risk/safety explanation and notice directing readers to newer 2026–2027 guidance.
limitations
Body still describes 2025–2026 decision language; used for pregnancy risk and update warning, not current schedule.
original id
covid-pregnancy
About Alcohol Use During Pregnancy ↗
id
pregnancy-prenatal--alcohol — About Alcohol Use During Pregnancy
kind
official
accessed at
2026-10-01
supports
Opened current CDC page: no known safe amount/time/type, variable outcomes, prevention after pregnancy recognition and continued checkups.
limitations
Cannot predict an individual outcome from a reported exposure.
original id
alcohol
Medicine and Pregnancy: An Overview ↗
id
pregnancy-prenatal--medicines — Medicine and Pregnancy: An Overview
kind
official
accessed at
2026-10-01
supports
Opened CDC advice to review prescriptions, OTC medicines, herbal/dietary supplements and vitamins before starting/stopping; untreated illness can also harm.
limitations
Many medicines lack adequate pregnancy safety evidence; no medicine-specific approval inferred.
original id
medicines
High Blood Pressure During Pregnancy ↗
id
pregnancy-prenatal--blood-pressure — High Blood Pressure During Pregnancy
kind
official
accessed at
2026-10-01
supports
Opened definitions and prenatal/postpartum blood-pressure significance, preeclampsia and related clinical features.
limitations
General education; no home diagnostic threshold or treatment algorithm supplied.
original id
blood-pressure
Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality: Preventive Medication ↗
id
pregnancy-prenatal--aspirin — Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality: Preventive Medication
kind
guideline
accessed at
2026-10-01
supports
Opened USPSTF 2021 recommendation/risk factors and evidence: 81 mg/day after 12 weeks for selected high-risk pregnancies; pooled preeclampsia RR 0.85.
limitations
Clinician prescribing, not universal supplement advice. Absolute benefit varies with baseline risk; prevention does not rule out later symptoms.
original id
aspirin
SMFM Consult Series #74 full guidance ↗
id
pregnancy-prenatal--genetic-detail — SMFM Consult Series #74 full guidance
kind
guideline
accessed at
2026-10-01
supports
Opened PDF relevant sections on placental DNA, false results, pretest counseling, confirmatory testing and CVS/amniocentesis tradeoffs for sex-chromosome results.
limitations
Relevant sections read, not every reference or full 25 pages line by line. Rare conditions have limited confirmation data; not a personal test decision.
original id
genetic-detail
Right-sizing prenatal care ↗
id
pregnancy-prenatal--care-preferences — Right-sizing prenatal care
kind
professional
accessed at
2026-10-01
supports
Peahl's public explanation of a 300-person postpartum preference study, between-visit contact and practical access barriers.
limitations
2020 institutional account; preferences do not demonstrate clinical safety or determine any patient's schedule.
original id
care-preferences
A Pragmatic Randomized Clinical Trial of Gestational Diabetes Screening ↗
id
pregnancy-prenatal--gdm-pathways — A Pragmatic Randomized Clinical Trial of Gestational Diabetes Screening
kind
study
accessed at
2026-10-01
supports
Opened Hillier et al. 2021 full author manuscript: 23,792 randomized pregnancies, diagnosis 16.5% vs 8.5%, no significant main outcome differences; adherence 66% vs 92%.
limitations
Two US integrated systems; nonadherence and threshold differences limit extrapolation. Compares two screened groups, not screening versus no screening.
original id
gdm-pathways
Treatment of Gestational Diabetes Mellitus Diagnosed Early in Pregnancy ↗
id
pregnancy-prenatal--early-gdm — Treatment of Gestational Diabetes Mellitus Diagnosed Early in Pregnancy
kind
study
accessed at
2026-10-01
supports
Opened Simmons et al. 2023 primary-trial abstract: 802 selected women with risk factor and early GDM; neonatal composite 24.9% vs 30.5%; no material hypertension/lean-body-mass differences.
limitations
Abstract only; treatment trial in an already selected/diagnosed group, not universal early-screening trial; composite not every component separately.
original id
early-gdm
Weight Gain During Pregnancy ↗
id
pregnancy-prenatal--weight — Weight Gain During Pregnancy
kind
official
accessed at
2026-10-01
supports
Explains BMI-specific ranges for singleton and twin pregnancies and the role of discussion with the care team.
limitations
Population ranges are not individual diagnosis, diet plan or moral judgment. No target range assigned to reader.
original id
weight
CDC Levels of Care Assessment Tool (CDC LOCATe) ↗
id
pregnancy-prenatal--care-setting — CDC Levels of Care Assessment Tool (CDC LOCATe)
kind
official
accessed at
2026-10-01
supports
Opened risk-appropriate facility care, specialist/equipment availability and variable state definitions; based on ACOG/SMFM/AAP guidance.
limitations
Public-health tool, not certification of any specific hospital or home/birth-centre setting.
original id
care-setting
Midwifery — University of Maryland School of Medicine ↗
id
pregnancy-prenatal--midwifery — Midwifery — University of Maryland School of Medicine
kind
professional
accessed at
2026-10-01
supports
Opened official patient explanation of CNM/physician teamwork, prenatal care, postpartum and nutrition education; Fahey named.
limitations
One service model; not proof all midwifery or obstetric settings have equivalent resources.
original id
midwifery
SMFM Statement: Response to FDA withdrawal of 17-alpha hydroxyprogesterone caproate ↗
id
pregnancy-prenatal--preterm — SMFM Statement: Response to FDA withdrawal of 17-alpha hydroxyprogesterone caproate
kind
guideline
accessed at
2026-10-01
supports
Opened 2023 statement reaffirmed 2025: April 5, 2023 withdrawal, discourage compounded 17-OHPC; distinct short-cervix progesterone/cerclage indications and shared-decision uncertainty remain.
limitations
Does not establish a prevention regimen for all prior preterm births or all pregnancy types.
original id
preterm
New center will tackle racial disparities in maternal health ↗
id
pregnancy-prenatal--equity — New center will tackle racial disparities in maternal health
kind
professional
accessed at
2026-10-01
supports
Opened Howell-led program account: care access, treatment standardization and postpartum coordination.
limitations
Institutional description of programs/research plans; does not prove every proposed program improves every outcome.
original id
equity
Alison M. Stuebe — official role and public contribution ↗
id
pregnancy-prenatal--panel-9 — Alison M. Stuebe — official role and public contribution
kind
professional
accessed at
2026-10-01
supports
MD, MSc; board-certified maternal-fetal medicine subspecialist, UNC researcher; Official public account describes fourth Trimester work and a patient-safety learning lab to redesign postnatal care.
limitations
2020 role announcement verifies training/research contribution, not all current administrative titles; lactation outcomes are not generalized to all prenatal questions.
original id
panel-9
Early pregnancy — public discussion ↗
id
pregnancy-prenatal--question-first-visit — Early pregnancy — public discussion
kind
question_signal
accessed at
2026-10-01
supports
Opened reader's question about an appointment a month away, folic acid and medicines; used to choose reader situations.
limitations
Anonymous self-report and comments are not factual authority, clinical advice or representative prevalence.
original id
question-first-visit
Any experiences with not gaining a lot of weight during twin pregnancy? ↗
id
pregnancy-prenatal--question-weight — Any experiences with not gaining a lot of weight during twin pregnancy?
kind
question_signal
accessed at
2026-10-01
supports
Opened worry about generic twin weight-gain ranges; informs nonjudgmental explanation.
limitations
Anecdotes cannot establish a safe weight target or fetal growth assessment.
original id
question-weight
Catherine Y. Spong — official role and public contribution ↗
id
pregnancy-prenatal--panel-1 — Catherine Y. Spong — official role and public contribution
kind
professional
accessed at
2026-10-01
supports
MD; maternal-fetal medicine specialist and UT Southwestern obstetrics/gynecology professor; Official public biography explains fetal-complication research and inclusion of pregnant people in studies.
limitations
Role/publication biography does not establish every treatment claim or offer individual prenatal care.
original id
panel-1
Mary E. D'Alton — official role and public contribution ↗
id
pregnancy-prenatal--panel-2 — Mary E. D'Alton — official role and public contribution
kind
professional
accessed at
2026-10-01
supports
MD; maternal-fetal medicine specialist, Columbia obstetrics/gynecology professor; Official patient biography describes multidisciplinary care and Safe Motherhood work; clinical textbook/editorial contributions are public teaching.
limitations
Current page describes former chair role historically; no current chair claim. Facility guidance, not biography, supports the reader's care-setting finding.
original id
panel-2
Uma M. Reddy — official role and public contribution ↗
id
pregnancy-prenatal--panel-3 — Uma M. Reddy — official role and public contribution
kind
professional
accessed at
2026-10-01
supports
MD, MPH; board-certified maternal-fetal medicine specialist; Yale obstetrics/gynecology professor; Public patient explanation and official research biography cover high-risk pregnancy, stillbirth and preterm-birth studies.
limitations
Population research cannot predict one pregnancy's outcome. Yale 2026 return verified; no old Columbia role treated as current.
original id
panel-3
Dwight J. Rouse — official role and public contribution ↗
id
pregnancy-prenatal--panel-4 — Dwight J. Rouse — official role and public contribution
kind
professional
accessed at
2026-10-01
supports
MD; maternal-fetal medicine and obstetrics/gynecology physician listed by Brown University Health; Brown's public CV documents professional teaching awards, guideline review and obstetric trial publications.
limitations
CV is dated 2019; used for historical teaching/contributions, not current professor titles. Current clinical specialties verified separately.
original id
panel-4
George R. Saade — official role and public contribution ↗
id
pregnancy-prenatal--panel-5 — George R. Saade — official role and public contribution
kind
professional
accessed at
2026-10-01
supports
MD; board-certified obstetrics/gynecology and maternal-fetal medicine physician; Old Dominion professor; Official biography documents maternal-fetal society education/advocacy, mentorship and perinatal editorial work.
limitations
Professional leadership is not individual prognosis; no article claim rests solely on his role.
original id
panel-5
Vincenzo Berghella — official role and public contribution ↗
id
pregnancy-prenatal--panel-6 — Vincenzo Berghella — official role and public contribution
kind
professional
accessed at
2026-10-01
supports
MD; Jefferson faculty physician in obstetrics/gynecology; maternal-fetal medicine field contributor; Public institutional publication record includes evidence reviews and obstetric research/editorial teaching.
limitations
Institutional publication list warns of automated attribution errors; verified selected topic contributions only. Treatment statement supplies current guidance.
original id
panel-6
Jeanne S. Sheffield — official role and public contribution ↗
id
pregnancy-prenatal--panel-7 — Jeanne S. Sheffield — official role and public contribution
kind
professional
accessed at
2026-10-01
supports
MD; Johns Hopkins professor of gynecology/obstetrics and maternal-fetal medicine division director; Official patient biography explicitly explains infectious-disease and immunization expertise.
limitations
Physician biography is not vaccine-schedule evidence; current CDC/ACOG documents determine products/timing.
original id
panel-7
Laura E. Riley — official role and public contribution ↗
id
pregnancy-prenatal--panel-8 — Laura E. Riley — official role and public contribution
kind
professional
accessed at
2026-10-01
supports
MD; maternal-fetal medicine specialist at Weill Cornell Medicine; Public biography and institutional interviews explain high-risk pregnancy and infectious-disease work.
limitations
Leadership and public reach do not replace vaccine safety data or product-specific recommendations.
original id
panel-8
Aaron B. Caughey — official role and public contribution ↗
id
pregnancy-prenatal--panel-10 — Aaron B. Caughey — official role and public contribution
kind
professional
accessed at
2026-10-01
supports
MD, PhD; OHSU obstetrics/gynecology professor; training in obstetric ultrasound; Public faculty/provider pages and listed research/policy teaching explain obstetric evidence and decision-making.
limitations
No claim that this profile establishes a universal delivery date or personal screening plan.
original id
panel-10
Alex F. Peahl — official role and public contribution ↗
id
pregnancy-prenatal--panel-11 — Alex F. Peahl — official role and public contribution
kind
professional
accessed at
2026-10-01
supports
MD, MSc; University of Michigan assistant professor of obstetrics/gynecology; Opened public interviews about tailored prenatal care and official clinical/research profile.
limitations
Institutional account is evidence translation; reduced visit schedules for average-risk populations cannot be assigned to all pregnancies.
original id
panel-11
Mary E. Norton — official role and public contribution ↗
id
pregnancy-prenatal--panel-12 — Mary E. Norton — official role and public contribution
kind
professional
accessed at
2026-10-01
supports
MD; UCSF perinatologist and clinical geneticist; Official public biography and research list address patient decisions, ultrasound and prenatal genetic testing.
limitations
Genetic-test expertise does not make every expanded commercial panel validated or guarantee a healthy infant.
original id
panel-12
Wanda K. Nicholson — official role and public contribution ↗
id
pregnancy-prenatal--panel-13 — Wanda K. Nicholson — official role and public contribution
kind
professional
accessed at
2026-10-01
supports
MD, MPH, MBA; obstetrician/gynecologist and epidemiologist; GW professor; Official biography describes perinatal diabetes/CVD research and public professional teaching in translating evidence into practice.
limitations
USPSTF recommendations are collective evidence assessments, not her personal advice; population risk does not prescribe treatment to a reader.
original id
panel-13
Jenifer O. Fahey — official role and public contribution ↗
id
pregnancy-prenatal--panel-14 — Jenifer O. Fahey — official role and public contribution
kind
professional
accessed at
2026-10-01
supports
CNM, MPH; certified nurse-midwife and University of Maryland faculty clinician; Official public patient-service pages explain prenatal/postpartum care; opened Maryland public workgroup minutes record hospital-based midwifery teaching.
limitations
Hospital-based service examples cannot establish the capability of every setting or credentials of all people called midwives.
original id
panel-14
Elizabeth A. Howell — official role and public contribution ↗
id
pregnancy-prenatal--panel-15 — Elizabeth A. Howell — official role and public contribution
kind
professional
accessed at
2026-10-01
supports
MD, MPP; Penn obstetrics/gynecology physician-researcher and maternal-health equity center leader; Opened public institutional explanations of maternal-health equity and continued care after pregnancy.
limitations
A described initiative or planned study is not evidence that every intervention works; no personal risk inferred from group disparities.
original id
panel-15
Dwight J. Rouse curriculum vitae (September 2019) ↗
id
pregnancy-prenatal--rouse-teaching — Dwight J. Rouse curriculum vitae (September 2019)
kind
professional
accessed at
2026-10-01
supports
Opened historical credentials, teaching awards and guideline/evidence review contributions.
limitations
Historical CV; no current administrative position inferred.
original id
rouse-teaching
Maryland Midwives Workgroup Meeting 4 minutes (December 3, 2012) ↗
id
pregnancy-prenatal--fahey-teaching — Maryland Midwives Workgroup Meeting 4 minutes (December 3, 2012)
kind
official
accessed at
2026-10-01
supports
Opened public minutes recording Fahey's hospital-based midwifery presentation.
limitations
Historical professional public education, not current regulation or clinical outcome evidence.
original id
fahey-teaching

Professional perspectives

Catherine Y. Spong
MD; maternal-fetal medicine specialist and UT Southwestern obstetrics/gynecology professor
Public usefulness
Official public biography explains fetal-complication research and inclusion of pregnant people in studies.
Contribution
Connects prenatal evidence literacy to the populations actually studied, rather than assuming every pregnancy is represented.
Scope and limits
Role/publication biography does not establish every treatment claim or offer individual prenatal care.
Reviewed
2026-10-01
Mary E. D'Alton
MD; maternal-fetal medicine specialist, Columbia obstetrics/gynecology professor
Public usefulness
Official patient biography describes multidisciplinary care and Safe Motherhood work; clinical textbook/editorial contributions are public teaching.
Contribution
Explains why staff, specialist access and referral capability matter for high-risk care.
Scope and limits
Current page describes former chair role historically; no current chair claim. Facility guidance, not biography, supports the reader's care-setting finding.
Reviewed
2026-10-01
Uma M. Reddy
MD, MPH; board-certified maternal-fetal medicine specialist; Yale obstetrics/gynecology professor
Public usefulness
Public patient explanation and official research biography cover high-risk pregnancy, stillbirth and preterm-birth studies.
Contribution
Shows how pregnancy history changes monitoring and why a screening result cannot replace continuing care.
Scope and limits
Population research cannot predict one pregnancy's outcome. Yale 2026 return verified; no old Columbia role treated as current.
Reviewed
2026-10-01
Dwight J. Rouse
MD; maternal-fetal medicine and obstetrics/gynecology physician listed by Brown University Health
Public usefulness
Brown's public CV documents professional teaching awards, guideline review and obstetric trial publications.
Contribution
Provides an evidence-method perspective: clinical trial populations/comparators matter more than a familiar protocol.
Scope and limits
CV is dated 2019; used for historical teaching/contributions, not current professor titles. Current clinical specialties verified separately.
Reviewed
2026-10-01
George R. Saade
MD; board-certified obstetrics/gynecology and maternal-fetal medicine physician; Old Dominion professor
Public usefulness
Official biography documents maternal-fetal society education/advocacy, mentorship and perinatal editorial work.
Contribution
Helps contextualize high-risk pregnancy trials and how evidence becomes professional guidance.
Scope and limits
Professional leadership is not individual prognosis; no article claim rests solely on his role.
Reviewed
2026-10-01
Vincenzo Berghella
MD; Jefferson faculty physician in obstetrics/gynecology; maternal-fetal medicine field contributor
Public usefulness
Public institutional publication record includes evidence reviews and obstetric research/editorial teaching.
Contribution
Preterm prevention and evidence synthesis support explaining why different progesterone formulations/indications are not interchangeable.
Scope and limits
Institutional publication list warns of automated attribution errors; verified selected topic contributions only. Treatment statement supplies current guidance.
Reviewed
2026-10-01
Jeanne S. Sheffield
MD; Johns Hopkins professor of gynecology/obstetrics and maternal-fetal medicine division director
Public usefulness
Official patient biography explicitly explains infectious-disease and immunization expertise.
Contribution
Adds pregnancy-specific infection and vaccine interpretation rather than a blanket vaccine rule.
Scope and limits
Physician biography is not vaccine-schedule evidence; current CDC/ACOG documents determine products/timing.
Reviewed
2026-10-01
Laura E. Riley
MD; maternal-fetal medicine specialist at Weill Cornell Medicine
Public usefulness
Public biography and institutional interviews explain high-risk pregnancy and infectious-disease work.
Contribution
Connects infection prevention to clinical pregnancy care and public explanation of immunization questions.
Scope and limits
Leadership and public reach do not replace vaccine safety data or product-specific recommendations.
Reviewed
2026-10-01
Alison M. Stuebe
MD, MSc; board-certified maternal-fetal medicine subspecialist, UNC researcher
Public usefulness
Official public account describes fourth Trimester work and a patient-safety learning lab to redesign postnatal care.
Contribution
Preserves the handoff from pregnancy to recovery, ongoing conditions and postpartum support.
Scope and limits
2020 role announcement verifies training/research contribution, not all current administrative titles; lactation outcomes are not generalized to all prenatal questions.
Reviewed
2026-10-01
Aaron B. Caughey
MD, PhD; OHSU obstetrics/gynecology professor; training in obstetric ultrasound
Public usefulness
Public faculty/provider pages and listed research/policy teaching explain obstetric evidence and decision-making.
Contribution
Adds a clinical-research/policy perspective on prenatal screening choices and outcome comparisons.
Scope and limits
No claim that this profile establishes a universal delivery date or personal screening plan.
Reviewed
2026-10-01
Alex F. Peahl
MD, MSc; University of Michigan assistant professor of obstetrics/gynecology
Public usefulness
Opened public interviews about tailored prenatal care and official clinical/research profile.
Contribution
MiPATH research examines how prenatal services can respond to medical risk and practical barriers to care.
Scope and limits
Institutional account is evidence translation; reduced visit schedules for average-risk populations cannot be assigned to all pregnancies.
Reviewed
2026-10-01
Mary E. Norton
MD; UCSF perinatologist and clinical geneticist
Public usefulness
Official public biography and research list address patient decisions, ultrasound and prenatal genetic testing.
Contribution
Clarifies the distinct jobs of a screening estimate and diagnostic confirmation.
Scope and limits
Genetic-test expertise does not make every expanded commercial panel validated or guarantee a healthy infant.
Reviewed
2026-10-01
Wanda K. Nicholson
MD, MPH, MBA; obstetrician/gynecologist and epidemiologist; GW professor
Public usefulness
Official biography describes perinatal diabetes/CVD research and public professional teaching in translating evidence into practice.
Contribution
Explains how to evaluate prevention evidence and maintain care from pregnancy through the postpartum period.
Scope and limits
USPSTF recommendations are collective evidence assessments, not her personal advice; population risk does not prescribe treatment to a reader.
Reviewed
2026-10-01
Jenifer O. Fahey
CNM, MPH; certified nurse-midwife and University of Maryland faculty clinician
Public usefulness
Official public patient-service pages explain prenatal/postpartum care; opened Maryland public workgroup minutes record hospital-based midwifery teaching.
Contribution
Explains collaborative midwifery care, informed choices and nutrition education.
Scope and limits
Hospital-based service examples cannot establish the capability of every setting or credentials of all people called midwives.
Reviewed
2026-10-01
Elizabeth A. Howell
MD, MPP; Penn obstetrics/gynecology physician-researcher and maternal-health equity center leader
Public usefulness
Opened public institutional explanations of maternal-health equity and continued care after pregnancy.
Contribution
Her work examines how access, communication and coordination among services affect maternal care.
Scope and limits
A described initiative or planned study is not evidence that every intervention works; no personal risk inferred from group disparities.
Reviewed
2026-10-01

Keep this topic in view

Preserved original record

The earlier public profile is preserved separately from the current article. It may contain superseded wording and is not newly checked material.

Read the full original profile

slug

pregnancy-prenatal

name

Pregnancy / prenatal

browse Line

Start prenatal care early and use folic acid unless a clinician says otherwise.

photo

/learn/assets/topics/pregnancy-prenatal.jpg

photo Alt

An adult sitting in a bright clinic waiting chair with a closed folder, looking toward a reception desk

aliases

prenatal care
folic acid pregnancy
first prenatal visit
gestational diabetes screening
Tdap pregnancy

family

home

heat

mid

talk

Sources

most Discussed

true

first Line

Prenatal care is health care during pregnancy for the pregnant person and developing baby. It includes appointments, screening and diagnostic tests, prevention, and knowing when symptoms need urgent help.

why Line

feel Words

first prenatal
how soon
dating ultrasound
prenatal visit
folic acid
Tdap
flu shot pregnancy
prenatal vitamin

common Picture

lead
Start prenatal care early rather than waiting for a perfect week
why
Early contact gives the prenatal team time to review medical history, medicines and supplements, establish pregnancy dates and plan the tests that fit. ACOG describes care tailored to the person rather than one rigid appointment pattern for everyone. Bring current medicine names and doses, previous pregnancy records and practical barriers such as transport or work hours. Ask who coordinates results and how urgent concerns are handled between appointments. Feeling well does not remove the need for this initial planning.
lead
Use folic acid and recommended vaccines unless a clinician says otherwise
why
Folic acid helps prevent neural-tube defects, so USPSTF emphasizes use before conception and during early pregnancy, when the neural tube develops. A prenatal vitamin may supply it, but the product and any higher-risk history should be reviewed. Vaccines have separate purposes and schedules: CDC recommends Tdap in each pregnancy and an appropriate seasonal flu vaccine. ACOG’s 2026 schedule also addresses COVID-19 and maternal RSV. Bring the vaccination record and ask which product and date apply; discuss any plans to start or stop other medicines with your clinician.
lead
Get urgent care for bleeding, severe headache, vision change, or a later drop in movement
why
Bleeding, severe headache, vision change, chest pain or a later drop in fetal movement needs urgent clinical care. CDC’s HEAR HER guidance covers serious warning signs during pregnancy and in the year after delivery. Contact the prenatal team or emergency care now rather than wait for a routine appointment or an online reply. Explain that you are pregnant or were pregnant recently, what changed and when. A page cannot determine the cause or rule out a serious complication from the symptom list.
lead
Ask which glucose, blood-pressure, and genetic screens apply to this pregnancy
why
Screening looks for increased risk or a possible problem; diagnostic testing is used to investigate or confirm a finding. USPSTF supports gestational-diabetes screening from 24 weeks, usually during weeks 24–28 in US care, while blood pressure is part of ongoing assessment. Genetic screening estimates the chance of selected conditions and is different from diagnostic procedures. Ask what each test can detect, its limits and what would follow an abnormal result. Preeclampsia prevention with aspirin is a separate clinician-selected treatment decision, not a screening test or routine vitamin.

situation Quick Answers

- label
  Arrange care
  value
  Contact a prenatal service early and bring medicines, supplements and relevant records.
- label
  Get the follow-up plan
  value
  Ask which visits and tests come next, who explains results and how urgent concerns are handled after hours.
- label
  Prevention
  value
  Review the folic-acid product and current pregnancy vaccine schedule with the care team.
- label
  Check the details
  value
  Bring supplement labels and vaccination dates; vaccine products and timing are specific to pregnancy and season.
- label
  Get urgent help
  value
  Bleeding, severe headache, vision change, chest pain or a later drop in fetal movement needs urgent clinical care.
- label
  Tell the receiving team
  value
  State that you are pregnant or were pregnant within the last year; do not wait for an online reply or routine visit.
- label
  Know the purpose
  value
  Ask what each glucose, blood-pressure or genetic test checks and when it is due.
- label
  Plan the result
  value
  Screening and diagnosis are different; ask what confirmation or follow-up an abnormal result would require.

picture Lead

Start prenatal care early rather than waiting for a perfect week

watch For

what People Say

Establish the prenatal care plan early. CDC, ACOG and WHO describe prenatal contact as a route to assessment, prevention and follow-up. The first conversation can identify medical concerns and practical barriers that change how visits are organized. Ask when to attend, which records to bring and how results will be explained, so the appointment becomes the start of a continuing care plan.
Check that folic acid is covered in the prevention plan. USPSTF recommends folic acid for people who plan to or could become pregnant because prevention begins before many pregnancies are recognized. The recommended average-risk amount differs from care for certain high-risk histories. Review the product label with the care team before combining supplements, and keep the focus on the specific preventive purpose.
Use a pregnancy-specific vaccine schedule. CDC and ACOG guidance distinguish recommended products from those avoided during pregnancy. Tdap is timed to help protect the newborn, while seasonal influenza vaccination protects against illness during pregnancy. Review the current schedule and vaccination history with the prenatal team; a recommendation for one product cannot be generalized to every vaccine bearing the same broad category name.
Use alcohol guidance as a prevention step. CDC states that no safe amount of alcohol during pregnancy is known. That is guidance for reducing avoidable exposure, not proof that a particular past exposure caused harm. If drinking occurred before pregnancy was recognized, discuss it honestly with the prenatal team and continue care; a personal story cannot establish a safe amount.
Understand what the glucose screening pathway does. Gestational diabetes is high blood glucose first identified during pregnancy. USPSTF supports screening from 24 weeks because identifying and treating it can improve selected maternal and infant outcomes. Some practices use an initial screening test followed by a diagnostic test; others use a one-step approach. Ask which test is ordered and what follow-up an abnormal result would require.
Seek urgent assessment for warning signs. CDC’s HEAR HER list includes severe headache, vision changes, chest pain, bleeding and reduced fetal movement, among other symptoms. These require a prompt clinical response, not a conclusion from a web checklist. Keep the care team’s urgent contact route available and tell the receiving clinician about the pregnancy or recent birth.

disputed Notes

Discuss weight gain in the context of the whole pregnancy. The National Academies’ ranges use prepregnancy BMI and differ for singleton and twin pregnancies. They are starting points for a conversation about nutrition, fetal growth and medical history. A single weigh-in cannot explain the cause of a change. Ask how the team will assess the trend and what support would help rather than treating a chart as a complete meal plan.
Choose genetic testing with a clear result plan. ACOG distinguishes screening estimates from diagnostic testing and supports informed choice. A positive screen does not by itself diagnose the condition. Ask what confirmation is available, what uncertainty might remain and how the information would affect care or preparation; counseling matters before testing as well as after a result.
Match the care setting to needs and available backup. Levels-of-maternal-care guidance connects pregnancy risk with the staff, equipment and referral arrangements a setting can provide. Preferences about midwifery or obstetric care can be discussed alongside that capability. Ask how a new complication would be recognized, who takes over and how transfer works, since a care setting must be able to respond when the initial plan changes.
Ask whether the aspirin prevention criteria apply. USPSTF supports low-dose aspirin for selected pregnancies at increased risk of preeclampsia. The individualized issue is eligibility and safe prescribing, not whether everyone should take it as a vitamin. A clinician reviews the risk factors, medical history and timing; this treatment does not replace blood-pressure assessment or urgent attention to warning symptoms.

talk Notes

Make contact before there is a problem to solve. Prenatal care includes time-sensitive prevention and planning even when symptoms are absent. ACOG and WHO explain why an initial assessment belongs early in the pregnancy. If care starts later, contact a service now and bring available records so the team can identify what remains useful and which follow-up needs priority.
Include supplements and herbal products in the medicine review. A prenatal team needs the actual ingredients, doses and frequency, not only the word natural on a label. CDC and ACOG treat medicine review as part of care. Bring the bottle or a clear ingredient list and ask what is known about pregnancy use; a product advertised for pregnancy is not automatically supported by pregnancy evidence.
Use the urgent contact route before seeking online reassurance. A symptom thread cannot measure blood pressure, examine bleeding or assess fetal wellbeing. CDC lists warning signs that require urgent care. Use the clinic’s after-hours instructions or emergency care as appropriate and state the pregnancy stage or recent delivery, rather than wait for a scheduled visit to raise a new warning sign.
Discuss a past alcohol exposure without delaying care. CDC’s prevention guidance is to avoid alcohol because no safe amount is known. A past exposure does not let a website predict the pregnancy’s outcome. Tell the prenatal team what occurred and ask for support if avoiding alcohol is difficult; continuing care is more useful than concealing the concern or relying on a relative’s experience.

how People Run It

Call to schedule prenatal care and bring a medicine list plus a folic-acid question. Arrange prenatal contact and bring a current medicine and supplement list, relevant records and vaccination history. Ask about the folic-acid plan, which appointments or tests come next, and how to reach urgent help between visits. Note who will explain results and where urgent concerns should go so the plan covers both scheduled care and unexpected symptoms.
Read the folic-acid amount on the product label. USPSTF’s average-risk recommendation concerns a specific nutrient and dose range, not an unlimited number of prenatal products. Bring the label and other supplements to the care team. A previous neural-tube-defect pregnancy or certain medicines needs individual advice rather than self-selected extra doses.
Save the urgent contact instructions. Ask the clinic which number is answered after hours and where to go if urgent symptoms occur. CDC’s warning-sign guidance applies between visits as well as during appointments. Put the instructions somewhere a support person can find them too, and do not wait for a callback if emergency care is needed.
Bring the vaccination history to the prenatal visit. The current pregnancy schedule depends on the vaccine, prior receipt, season and gestational age. CDC and ACOG provide product-specific guidance. Ask the team to record the recommended dates and discuss any concern or previous reaction, rather than apply one blanket rule to all vaccines.

how People Keep It

Keep one clear route for routine follow-up. ACOG’s prenatal care approach connects the history, tests and later visits. Know who receives outside results and how a missed appointment will be rescheduled. This prevents a completed test from becoming information nobody has discussed with you.
Keep the purpose of folic acid clear. Folic acid reduces the risk of neural-tube defects during early development. USPSTF’s recommendation is preventive and does not treat an established structural finding. Keep the agreed supplement plan with the medicine list so changes can be reviewed without accidentally duplicating products.
Keep vaccine timing with the care record. A vaccine name alone does not show whether the intended pregnancy dose or seasonal dose has been given. CDC and ACOG schedules specify timing and product. Record the administration date and bring it to later appointments so the care team can see what is complete and what remains due.
Keep warning signs and the urgent route together. The useful reminder pairs symptoms with an action: bleeding, severe headache, vision change, chest pain or a later reduction in movement needs urgent clinical care. CDC also reminds people to report a recent pregnancy after delivery. A saved list should support getting help, not become a checklist for ruling out danger at home.
Keep a short list of results and unanswered questions. Prenatal screening can lead to further testing, monitoring or reassurance with specific limits. Record what was checked, who explained it and the next planned step. This makes the next appointment easier to use and helps the care team distinguish a completed test from a follow-up question that is still open.

claims Notes

Start prenatal care early rather than waiting for a perfect week. Claim: “Early prenatal care is the field's starting step” — established. Early prenatal contact establishes the medical history, medicine review, prevention and screening plan. ACOG now describes tailored care delivery rather than a fixed schedule for every person. Ask which appointments are needed, how results are followed and how urgent concerns are handled between visits.
Take folic acid as recommended unless told otherwise. Claim: “Folic acid is recommended to prevent neural-tube defects for people who could become pregnant” — established. USPSTF supports folic acid before conception and during early development because the neural tube closes early. Its standard dose range applies to average-risk people; previous affected pregnancy and other high-risk circumstances require a different clinical assessment. Review the actual supplement label with the care team.
Use recommended vaccines in pregnancy. Claim: “Vaccines are never used in pregnancy” — not what the research found. CDC and ACOG recommend specific vaccines during pregnancy, with different timing and product requirements. Tdap and an appropriate seasonal flu vaccine are examples. Use the current pregnancy schedule and vaccination record to identify what applies rather than a blanket rule about all vaccines.
Treat alcohol as no known safe amount in pregnancy. Claim: “A little alcohol in pregnancy has a known safe amount” — not what the research found. CDC has not identified a safe amount of alcohol during pregnancy. That supports avoidance and an honest clinical discussion about past exposure; it does not allow a website to predict an individual outcome. Ask for help if stopping is difficult.
Get urgent care for bleeding, severe headache, vision change, or a later drop in movement. Claim: “Severe headache with vision change can wait for the next scheduled visit” — not what the research found. Severe headache with vision change needs urgent clinical assessment. CDC’s warning-sign guidance is intended to prompt help during pregnancy and after delivery, not to support waiting for a routine visit. State that you are pregnant or recently pregnant when contacting urgent or emergency care.
Screen for gestational diabetes on the ordinary schedule. Claim: “Gestational-diabetes screening is ordinary prenatal care in most US pathways” — established. USPSTF supports screening at 24 weeks or later, usually 24–28 weeks in US care. The next step depends on whether the ordered test is an initial screen or a diagnostic test. Ask the team how the result will be communicated and what follow-up is needed.
Use low-dose aspirin only when a clinician says the risk fits. Claim: “Low-dose aspirin is a general pregnancy vitamin” — not what the research found. USPSTF supports low-dose aspirin for selected pregnancies at increased preeclampsia risk. The indication and safe prescribing plan are individual clinical decisions. It is not a universal prenatal supplement and does not replace assessment of warning signs.

deep Dive

Start neural-tube prevention before the early closure window. The neural tube, which develops into the brain and spinal cord, closes early in pregnancy; a defect results when closure is incomplete. USPSTF’s average-risk guidance recommends 400–800 micrograms of folic acid daily, beginning at least one month before conception and continuing through the first two to three months. Some higher-risk histories fall outside this standard recommendation and require individual advice. A prenatal label should be read for the nutrient amount rather than assumed adequate from the product name.
Read the vaccine product and timing together. CDC recommends Tdap during each pregnancy, preferably early in weeks 27–36, and an inactivated or recombinant influenza vaccine during the relevant season. ACOG’s June 2026 schedule also recommends COVID-19 vaccination and describes maternal RSV vaccination with Abrysvo during a specific late-pregnancy and seasonal window for eligible patients. Previous maternal RSV vaccination changes the later-pregnancy plan. These are product-specific professional recommendations to review with the prenatal team, not a rule to repeat every vaccine during every pregnancy.
Understand aspirin as targeted preeclampsia prevention. Preeclampsia involves pregnancy-related hypertension with additional clinical features and can become serious. USPSTF supports low-dose aspirin for selected higher-risk pregnancies; the team reviews factors such as previous preeclampsia, chronic hypertension and other relevant conditions. Eligibility, timing and contraindications require a prescribing decision. Even an appropriate preventive prescription cannot rule out later disease, so symptoms and blood-pressure follow-up still require the planned clinical response.
Separate the glucose screen from the diagnosis and follow-up. USPSTF supports gestational-diabetes screening at 24 weeks or later; US testing is usually at 24–28 weeks. In a two-step pathway, an abnormal initial glucose challenge leads to a diagnostic tolerance test, while a one-step pathway uses a diagnostic test directly. Earlier assessment for possible pre-existing diabetes is a different clinical question. If gestational diabetes is diagnosed, the care plan can include nutrition support, glucose monitoring and medication when indicated, with a discussion of follow-up after pregnancy.
Read a weight-gain range as a guide to a trend. National Academies guidance uses prepregnancy BMI and pregnancy type to describe recommended ranges. It does not turn each week’s weight into a verdict about health or fetal growth. Nausea, intake, fluid changes and medical conditions may need different attention from the care team. Ask what the overall trend means and whether nutrition or other support is needed, especially when a generic chart does not fit the circumstances.
Ask what a care setting can do if risk changes. Levels-of-maternal-care work associated with D’Alton and professional organizations concerns matching clinical needs to available resources. A setting’s transfer arrangement, emergency response and access to specialist care matter alongside the preferred birth experience. Ask who assesses a new complication and where care would move if additional capability is needed. This makes the backup plan explicit without assuming that every pregnancy requires the same facility.
Distinguish current preterm-prevention options from withdrawn treatment. SMFM’s statement, reaffirmed in 2025, explains that FDA withdrew 17-OHPC in April 2023 because evidence did not establish prevention of recurrent spontaneous preterm birth. SMFM discourages continued prescribing, including compounded formulations. This does not erase selected indications for vaginal progesterone with a short cervix or for cerclage. The relevant choice depends on history, cervical assessment and pregnancy type; an old protocol using the word progesterone should not be treated as a current interchangeable instruction.
Use the alcohol recommendation without inventing an individual prognosis. CDC’s no-known-safe-amount guidance supports avoiding further exposure. It cannot identify the outcome of one past episode from a date or drink count supplied online. A calm, specific discussion with the prenatal team can review the exposure and any support needed to stop. Continue recommended care and bring questions directly to the clinician instead of treating either reassurance or alarm from an anecdote as a diagnosis.
Carry the safety plan into the year after delivery. CDC’s HEAR HER guidance reminds people that serious pregnancy-related problems can occur after birth, including within the following year. Keep the urgent contact route and tell a clinician about the recent pregnancy when a warning symptom appears. Routine postpartum follow-up should also address recovery, medicines and ongoing conditions. Ending pregnancy care should therefore include a handoff to continued care, not only a completed delivery record.

related

nutrition
sleep
fitness

watch For Long

Good to know. This is a reading companion, not prenatal care, not a birth plan, and not an intimacy guide. Bleeding, severe headache, vision change, chest pain, or a later drop in fetal movement needs urgent clinical care. Do not start or stop medicines from this text. This page does not treat one pregnancy.
Not advice. Named sources. Honest paraphrase of the finding. Not medical, legal, or financial advice.

sources

Catherine Spong. maternal-fetal medicine physician. Relevant work: prenatal evidence translation.
Mary D'Alton. maternal-fetal medicine physician. Relevant work: levels of maternal care.
Uma Reddy. maternal-fetal medicine physician. Relevant work: stillbirth and prenatal-research leadership.
Dwight Rouse. maternal-fetal medicine physician. Relevant work: obstetric trial evidence.
George Saade. maternal-fetal medicine physician. Relevant work: high-risk pregnancy research.
Vincenzo Berghella. maternal-fetal medicine physician. Relevant work: preterm-birth prevention evidence.
Jeanne Sheffield. maternal-fetal medicine physician; vaccines in pregnancy. Relevant work: immunization in pregnancy.
Laura Riley. obstetrician; infection and pregnancy. Relevant work: infection-prevention teaching.
Alison Stuebe. obstetrician; postpartum and lactation research. Relevant work: postpartum care as part of the continuum.
Aaron Caughey. maternal-fetal medicine physician. Relevant work: prenatal screening and delivery-timing evidence.
Christopher Zahn. obstetrician; ACOG clinical leadership. Relevant work: ACOG clinical guidance translation.
Wanda Barfield. pediatrician; CDC Division of Reproductive Health. Relevant work: CDC pregnancy public-health pages.
USPSTF folic-acid reviewers. US Preventive Services Task Force folic-acid recommendation. Relevant work: folic acid to prevent neural-tube defects.
American College of Obstetricians and Gynecologists. professional obstetric society. Relevant work: prenatal-care committee opinions.
CDC pregnancy public-health authors. CDC pregnancy and vaccination pages. Relevant work: vaccines, alcohol, and warning-sign education.

source Links

CDC-PREG

name

Centers for Disease Control and Prevention. Pregnancy public-health hub.

kind

evidence

links

label
Source
href
https://www.cdc.gov/pregnancy/

ACOG-PRENATAL

name

American College of Obstetricians and Gynecologists. Prenatal care committee opinions and patient pages.

kind

evidence

links

label
Source
href
https://www.acog.org/womens-health/faqs/prenatal-care

USPSTF-FOLATE

name

US Preventive Services Task Force. Folic Acid Supplementation to Prevent Neural Tube Defects.

kind

evidence

links

label
Source
href
https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/folic-acid-for-the-prevention-of-neural-tube-defects-preventive-medication

CDC-ALCOHOL

name

CDC. Alcohol use in pregnancy.

kind

evidence

links

label
Source
href
https://www.cdc.gov/alcohol/about-alcohol-use/alcohol-and-pregnancy.html

CDC-VACCINES

name

CDC. Vaccines during pregnancy, including Tdap and influenza.

kind

evidence

links

label
Source
href
https://www.cdc.gov/vaccines-pregnancy/hcp/conversation-tips/index.html

USPSTF-ASPIRIN

name

USPSTF. Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality.

kind

evidence

links

label
Source
href
https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/low-dose-aspirin-use-for-the-prevention-of-morbidity-and-mortality-from-preeclampsia-preventive-medicine

ACOG-GDM

name

ACOG. Gestational diabetes mellitus screening and care guidance.

kind

evidence

links

label
Source
href
https://www.acog.org/

SMFM-WARNING

name

SMFM and allied public education on when to seek care.

kind

evidence

links

label
Source
href
https://www.smfm.org/

WHO-ANC

name

World Health Organization. WHO recommendations on antenatal care for a positive pregnancy experience.

kind

evidence

links

label
Source
href
https://www.who.int/publications/i/item/9789241549912

NAM-WEIGHT

name

Institute of Medicine / National Academy of Medicine. Weight Gain During Pregnancy: Reexamining the Guidelines.

kind

evidence

links

label
Source
href
https://pubmed.ncbi.nlm.nih.gov/?term=IOM+weight+gain+pregnancy+2009

SPONG-PREG-2026

name

Catherine Spong

kind

professional

links

label
Source
href
https://pubmed.ncbi.nlm.nih.gov/?term=Spong+CY+pregnancy

DALTON-PREG-2026

name

Mary D'Alton

kind

professional

links

label
Source
href
https://pubmed.ncbi.nlm.nih.gov/?term=D%27Alton+ME+pregnancy

REDDY-PREG-2026

name

Uma Reddy

kind

professional

links

label
Source
href
https://pubmed.ncbi.nlm.nih.gov/?term=Reddy+UM+pregnancy

ROUSE-PREG-2026

name

Dwight Rouse

kind

professional

links

label
Source
href
https://pubmed.ncbi.nlm.nih.gov/?term=Rouse+DJ+pregnancy

SAADE-PREG-2026

name

George Saade

kind

professional

links

label
Source
href
https://pubmed.ncbi.nlm.nih.gov/?term=Saade+GR+pregnancy

BERGHELLA-PREG-2026

name

Vincenzo Berghella

kind

professional

links

label
Source
href
https://pubmed.ncbi.nlm.nih.gov/?term=Berghella+V+preterm

SHEFFIELD-PREG-2026

name

Jeanne Sheffield

kind

professional

links

label
Source
href
https://pubmed.ncbi.nlm.nih.gov/?term=Sheffield+JS+vaccine+pregnancy

RILEY-PREG-2026

name

Laura Riley

kind

professional

links

label
Source
href
https://pubmed.ncbi.nlm.nih.gov/?term=Riley+LE+pregnancy

STUEBE-PREG-2026

name

Alison Stuebe

kind

professional

links

label
Source
href
https://pubmed.ncbi.nlm.nih.gov/?term=Stuebe+AM+pregnancy

CAUGHEY-PREG-2026

name

Aaron Caughey

kind

professional

links

label
Source
href
https://pubmed.ncbi.nlm.nih.gov/?term=Caughey+AB+pregnancy

ZAHN-PREG-2026

name

Christopher Zahn

kind

professional

links

label
Source
href
https://www.acog.org/

BARFIELD-PREG-2026

name

Wanda Barfield

kind

professional

links

label
Source
href
https://www.cdc.gov/pregnancy/

USPSTF-PREG-2026

name

USPSTF folic-acid reviewers

kind

professional

links

label
Source
href
https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/folic-acid-for-the-prevention-of-neural-tube-defects-preventive-medication

ACOG-PREG-2026

name

American College of Obstetricians and Gynecologists

kind

professional

links

label
Source
href
https://www.acog.org/

CDC-PREG-2026

name

CDC pregnancy public-health authors

kind

professional

links

label
Source
href
https://www.cdc.gov/pregnancy/

ACOG-TAILORED-2025-SEARCH

name

ACOG: New Guidance on Prenatal Care Delivery. Source

kind

evidence

links

label
Source
href
https://www.acog.org/news/news-releases/2025/04/new-acog-guidance-recommends-transformation-to-us-prenatal-care-delivery

USPSTF-FOLATE-2023-EXACT

name

USPSTF: Folic Acid Supplementation to Prevent Neural Tube Defects. Source

kind

evidence

links

label
Source
href
https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/folic-acid-for-the-prevention-of-neural-tube-defects-preventive-medication

CDC-VACCINES-PREG-2025

name

CDC: Guidelines for Vaccinating Pregnant Women. Source

kind

evidence

links

label
Source
href
https://www.cdc.gov/vaccines-pregnancy/hcp/vaccination-guidelines/index.html

ACOG-VACCINE-SCHEDULE-2026

name

ACOG 2026 Maternal Immunization Schedule. Source

kind

evidence

links

label
Source
href
https://cdn.ymaws.com/npwh.org/resource/resmgr/resources/ACOG_2026_Maternal_Immunizat.pdf

CDC-HEARHER-EXACT

name

CDC: Urgent Maternal Warning Signs and Symptoms. Source

kind

evidence

links

label
Source
href
https://www.cdc.gov/hearher/maternal-warning-signs/index.html

USPSTF-GDM-2021-EXACT

name

USPSTF: Gestational Diabetes Screening. Source

kind

evidence

links

label
Source
href
https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/gestational-diabetes-screening

ACOG-GENETIC-2026-SEARCH

name

ACOG: Current Guidance on Prenatal Screening. Source

kind

evidence

links

label
Source
href
https://www.acog.org/advocacy/policy-priorities/non-invasive-prenatal-testing/current-acog-guidance

USPSTF-ASPIRIN-2021-EXACT

name

USPSTF: Aspirin Use to Prevent Preeclampsia. Source

kind

evidence

links

label
Source
href
https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/low-dose-aspirin-use-for-the-prevention-of-morbidity-and-mortality-from-preeclampsia-preventive-medication

SMFM-17OHPC-2023-R2025

name

SMFM response to FDA withdrawal of 17-OHPC, reaffirmed 2025. Source

kind

evidence

links

label
Source
href
https://publications.smfm.org/publications/467-society-for-maternal-fetal-medicine-statement-response-to/

source Claims

watch For

CDC-PREG
ACOG-PRENATAL
SPONG-PREG-2026

situations.first-visit

CDC-PREG
ACOG-PRENATAL
WHO-ANC
SPONG-PREG-2026
CAUGHEY-PREG-2026
ACOG-TAILORED-2025-SEARCH

situations.vitamins-vaccines

USPSTF-FOLATE
CDC-VACCINES
SHEFFIELD-PREG-2026
RILEY-PREG-2026
USPSTF-PREG-2026
USPSTF-FOLATE-2023-EXACT
CDC-VACCINES-PREG-2025
ACOG-VACCINE-SCHEDULE-2026

situations.warning-signs

CDC-PREG
SMFM-WARNING
ACOG-PRENATAL
DALTON-PREG-2026
CDC-HEARHER-EXACT

situations.screening

ACOG-GDM
USPSTF-ASPIRIN
REDDY-PREG-2026
ROUSE-PREG-2026
ACOG-PREG-2026
USPSTF-GDM-2021-EXACT
ACOG-GENETIC-2026-SEARCH
USPSTF-ASPIRIN-2021-EXACT

split.established.0

CDC-PREG
ACOG-PRENATAL
WHO-ANC
SPONG-PREG-2026

split.established.1

USPSTF-FOLATE
CDC-PREG
USPSTF-PREG-2026
USPSTF-FOLATE-2023-EXACT

split.established.2

CDC-VACCINES
SHEFFIELD-PREG-2026
RILEY-PREG-2026
CDC-PREG-2026
CDC-VACCINES-PREG-2025
ACOG-VACCINE-SCHEDULE-2026

split.established.3

CDC-ALCOHOL
CDC-PREG
ACOG-PRENATAL

split.established.4

ACOG-GDM
CAUGHEY-PREG-2026
ACOG-PREG-2026
USPSTF-GDM-2021-EXACT

split.established.5

CDC-PREG
SMFM-WARNING
DALTON-PREG-2026
CDC-HEARHER-EXACT

split.disputed.0

NAM-WEIGHT
STUEBE-PREG-2026
ACOG-PRENATAL

split.disputed.1

ACOG-PRENATAL
CAUGHEY-PREG-2026
ZAHN-PREG-2026
ACOG-GENETIC-2026-SEARCH

split.disputed.2

DALTON-PREG-2026
ACOG-PRENATAL
WHO-ANC
SMFM-WARNING

split.disputed.3

USPSTF-ASPIRIN
SAADE-PREG-2026
SMFM-WARNING
USPSTF-ASPIRIN-2021-EXACT

split.talk.0

CDC-PREG
ACOG-PRENATAL
WHO-ANC

split.talk.1

CDC-PREG
ACOG-PRENATAL
USPSTF-FOLATE

split.talk.2

SMFM-WARNING
CDC-PREG
DALTON-PREG-2026
CDC-HEARHER-EXACT

split.talk.3

CDC-ALCOHOL
CDC-PREG

move

CDC-PREG
ACOG-PRENATAL
USPSTF-FOLATE
USPSTF-FOLATE-2023-EXACT
CDC-HEARHER-EXACT

try.0

USPSTF-FOLATE
CDC-PREG
USPSTF-FOLATE-2023-EXACT

try.1

SMFM-WARNING
CDC-PREG
CDC-HEARHER-EXACT

try.2

CDC-VACCINES
SHEFFIELD-PREG-2026
CDC-VACCINES-PREG-2025
ACOG-VACCINE-SCHEDULE-2026

keep.0

CDC-PREG
ACOG-PRENATAL
WHO-ANC

keep.1

USPSTF-FOLATE
USPSTF-PREG-2026
USPSTF-FOLATE-2023-EXACT

keep.2

CDC-VACCINES
SHEFFIELD-PREG-2026
CDC-VACCINES-PREG-2025

keep.3

SMFM-WARNING
CDC-PREG
CDC-HEARHER-EXACT

keep.4

ACOG-PRENATAL
CDC-PREG
ACOG-GENETIC-2026-SEARCH

deep.0

USPSTF-FOLATE
USPSTF-PREG-2026
CDC-PREG
USPSTF-FOLATE-2023-EXACT

deep.1

CDC-VACCINES
SHEFFIELD-PREG-2026
CDC-PREG-2026
CDC-VACCINES-PREG-2025
ACOG-VACCINE-SCHEDULE-2026

deep.2

USPSTF-ASPIRIN
SAADE-PREG-2026
SMFM-WARNING
USPSTF-ASPIRIN-2021-EXACT

deep.3

ACOG-GDM
CAUGHEY-PREG-2026
USPSTF-GDM-2021-EXACT

deep.4

NAM-WEIGHT
STUEBE-PREG-2026

deep.5

DALTON-PREG-2026
ACOG-PRENATAL
SMFM-WARNING

deep.6

BERGHELLA-PREG-2026
ROUSE-PREG-2026
SMFM-WARNING
SMFM-17OHPC-2023-R2025

deep.7

CDC-ALCOHOL
BARFIELD-PREG-2026
CDC-PREG

deep.8

ACOG-PRENATAL
CDC-PREG
ZAHN-PREG-2026
CDC-HEARHER-EXACT

claims.0

CDC-PREG
ACOG-PRENATAL
WHO-ANC
ACOG-TAILORED-2025-SEARCH

claims.1

USPSTF-FOLATE
CDC-PREG
USPSTF-FOLATE-2023-EXACT

claims.2

CDC-VACCINES
SHEFFIELD-PREG-2026
CDC-VACCINES-PREG-2025
ACOG-VACCINE-SCHEDULE-2026

claims.3

CDC-ALCOHOL

claims.4

CDC-PREG
SMFM-WARNING
DALTON-PREG-2026
CDC-HEARHER-EXACT

claims.5

ACOG-GDM
CAUGHEY-PREG-2026
USPSTF-GDM-2021-EXACT

claims.6

USPSTF-ASPIRIN
SAADE-PREG-2026
USPSTF-ASPIRIN-2021-EXACT

source Situation Keys

situations.first-visit
situations.vitamins-vaccines
situations.warning-signs
situations.screening

professional Source Ids

SPONG-PREG-2026
DALTON-PREG-2026
REDDY-PREG-2026
ROUSE-PREG-2026
SAADE-PREG-2026
BERGHELLA-PREG-2026
SHEFFIELD-PREG-2026
RILEY-PREG-2026
STUEBE-PREG-2026
CAUGHEY-PREG-2026
ZAHN-PREG-2026
BARFIELD-PREG-2026
USPSTF-PREG-2026
ACOG-PREG-2026
CDC-PREG-2026

house Pointers

href
/self/
label
STUDself. For everyday sleep and food habits, see STUDself.

positive Guidance

status: DONE
reviewed At: 2026-09-18
professional Count: 15
scope: content-and-positive-titles-only

learn Article

article

format version

presentation

complete-card

overview

sections

id
understanding-prenatal-care
role
explanation
title
What prenatal care helps you understand
intro
Prenatal means before birth; antenatal means the same thing. Care follows both the pregnant person's health and the developing baby's health. An appointment, a preventive treatment, a screening test and an urgent assessment have different jobs. These four familiar situations show why that distinction matters.
items
- label
  Make early contact so the team can plan the right care
  text
  If you have a positive pregnancy test and feel well, you can still contact a prenatal service now and ask when assessment should begin. WHO describes antenatal care as continuing assessment, prevention, symptom support and education, rather than a visit reserved for illness. Medical history, previous pregnancies and current medicines can change what needs attention first. Ask how pregnancy dates will be established, because test and vaccine windows depend on how far along the pregnancy is. Tell the service about those concerns when booking, even if its first routine appointment is several weeks away. Ask what to do while waiting, who explains results and how to reach help after hours. If care starts later than expected, make contact now; missed time is a reason to prioritize remaining care, not to abandon it.
  source ids
  who-care
  prenatal-care
- label
  Review prevention while you are waiting for the first visit
  text
  A prenatal vitamin, a vaccine and a prescription prevent different problems. Folic acid has evidence for reducing particular early brain and spinal-cord defects; it is not a promise that every pregnancy complication is prevented. Tdap helps protect an infant against whooping cough, and its pregnancy timing differs from the seasonal flu vaccine. Bring supplement ingredients and vaccination dates so the team can see what is already covered and what applies next. Do not assume that the word prenatal on a product establishes its contents, or that a previous adult vaccine dose completes every pregnancy recommendation.
  source ids
  folic-clinical
  acog-vaccines
- label
  Use urgent assessment when a symptom changes
  text
  A severe headache with vision changes, chest pain, bleeding or a change in the baby's usual movement is a different question from scheduling the next routine checkup. CDC's HEAR HER campaign directs people with maternal warning signs to seek care promptly during pregnancy and up to a year afterward. A clinician may need an examination, blood-pressure measurement or fetal assessment to explain the symptom. A reassuring comment online cannot do those things. State the pregnancy stage or recent delivery and when the change began; emergency symptoms need emergency care rather than a routine appointment or an online reply.
  source ids
  warning-signs
- label
  Ask what each test can tell you and what follows the result
  text
  If you are offered blood tests, an ultrasound or genetic testing, the important first question is what each one is checking. Screening identifies a possible problem or estimates a chance; diagnosis investigates or confirms a specific condition. An abnormal initial glucose screen can lead to a longer diagnostic test, while a genetic blood screen can lead to counseling and a different kind of confirmatory test. Ask what a positive, negative or unclear result means and who will contact you. A result is useful when its limits and follow-up are explained, not simply when it appears in a portal.
  source ids
  gdm
  genetic-screening
id
prevention-with-a-purpose
role
findings
title
What the prevention findings actually mean
intro
Prevention aims to lower a risk before a problem develops. It can be useful without being a guarantee, and its dose, timing and eligible population are part of the finding.
items
- label
  Cover folic acid before the early development window
  text
  The neural tube is the early structure that becomes the brain and spinal cord. When it does not close completely, neural-tube defects can result; closure occurs very early, often before pregnancy is recognized. In its 2023 evidence-based recommendation, USPSTF recommends a daily supplement containing 400–800 micrograms of folic acid for average-risk people who plan to or could become pregnant, starting at least one month before conception and continuing through the first two to three months. This reduces risk rather than eliminating it. A previous affected pregnancy, relevant family history or medicines that interfere with folic acid falls outside that standard recommendation and needs individual clinical review.
  source ids
  folic-acid
- label
  Read the nutrient and amount rather than relying on the brand name
  text
  Folate is vitamin B9; folic acid is a form used in supplements and fortified foods with neural-tube-prevention evidence. A label can show several folate terms, so bring the actual label if the amount is unclear. CDC explains that common MTHFR gene variants do not stop the body processing folic acid; an internet genetics result is not, by itself, a reason to replace the established prevention approach. More products do not automatically mean more protection. Review overlapping vitamins and any higher-risk history with the team rather than selecting extra doses yourself. Starting later cannot turn back an early development window, but it is still worth discussing your current nutrition and care needs.
  source ids
  folic-label
  mthfr
  folic-clinical
- label
  Match each vaccine to its pregnancy purpose and timing
  text
  Maternal vaccination can protect the pregnant person and, through antibodies passed before birth, help protect an infant. CDC recommends Tdap in each pregnancy, preferably early in weeks 27–36; a prior adult dose does not replace that pregnancy dose. An inactivated or recombinant flu vaccine is recommended during the relevant season; the live nasal-spray product is different. For eligible pregnancies, maternal RSV prevention uses Abrysvo at 32 weeks 0 days through 36 weeks 6 days, seasonally—September through January in most of the continental US. Other adult RSV products are not interchangeable. Prior maternal RSV vaccination changes the later pregnancy/infant prevention plan. Ask the team to record the product, date and purpose, including any regional seasonal differences.
  source ids
  vaccines
- label
  Use the current seasonal vaccine guidance with your care team
  text
  ACOG's 2026 maternal schedule includes COVID-19 vaccination and allows it during any trimester. CDC's newer 2026–2027 clinical considerations recommend a seasonal COVID-19 vaccine for adults and ask patients and clinicians to discuss benefits and risks. Pregnancy increases the risk of severe COVID-19 illness, which is part of that discussion. Older public pages may still describe the previous season, so the date and linked current schedule matter. The practical question is which current product and timing fit your vaccination history and health, including any prior reaction. Reading a page does not establish your individual product eligibility or dose.
  source ids
  acog-vaccines
  covid-current
  covid-pregnancy
- label
  Use alcohol prevention without making a prediction about the past
  text
  CDC has not identified a safe amount, time or type of alcohol during pregnancy. Alcohol can reach the developing fetus, and pregnancies do not all respond to exposure in the same way. The prevention recommendation is therefore to avoid alcohol, not to use a relative's healthy child as evidence for a safe allowance. If you drank before knowing you were pregnant, tell the prenatal team what occurred and continue care. That disclosure helps a clinical conversation; it does not let a website predict damage or guarantee reassurance. If avoiding alcohol is difficult, ask the clinician for support promptly rather than trying to manage the concern through shame or concealment.
  source ids
  alcohol
- label
  Review medicines by balancing treatment and untreated illness
  text
  A medicine review includes prescriptions, nonprescription products, herbal remedies, dietary supplements and vitamins. CDC emphasizes that stopping a needed medicine can sometimes be more harmful than taking it, while some medicines can pose pregnancy risks. The decision depends on the condition being treated, the actual ingredient and dose, pregnancy timing and available evidence. A natural label supplies none of that comparison. Bring bottles or an accurate list with doses and frequency, and contact the prescribing and prenatal teams before starting or stopping treatment. Gaps in research mean uncertainty needs explanation; they do not mean every exposure is safe or every treatment should be abandoned.
  source ids
  medicines
id
screening-and-follow-up
role
findings
title
How the main prenatal assessments work
intro
Tests answer specific questions. Understanding the question makes both reassuring and abnormal results easier to use.
items
- label
  Understand the glucose pathway before interpreting the number
  text
  Gestational diabetes means high blood glucose first diagnosed during pregnancy. Pregnancy can make the body less responsive to insulin, the hormone that helps move glucose out of the blood. USPSTF supports screening in people without known type 1 or type 2 diabetes at 24 weeks or later, commonly 24–28 weeks in US care. In a two-step pathway, a shorter initial glucose challenge is followed by an oral glucose-tolerance test if needed. A one-step pathway uses a diagnostic tolerance test directly. The drink, fasting instructions and number of blood samples depend on the pathway. Ask which test you are having; an abnormal screening value and a diagnosis are different pieces of information.
  source ids
  gdm
- label
  Keep blood-pressure assessment separate from aspirin prevention
  text
  Blood pressure is the force of circulating blood against artery walls. Pregnancy-related high blood pressure sometimes accompanies preeclampsia, a disorder that can also involve organ problems or other clinical findings. Monitoring helps the team identify change; aspirin is a separate preventive treatment for selected people at increased risk. USPSTF recommends clinician-prescribed low-dose aspirin after 12 weeks for eligible high-risk pregnancies, with US guidance specifying 81 mg daily. Previous preeclampsia, chronic hypertension and certain other medical histories affect eligibility. The task force's trial synthesis found fewer preeclampsia cases in high-risk groups, not universal protection. Ask whether the criteria fit your history; do not start aspirin from this article, and keep reporting symptoms even if it is prescribed.
  source ids
  blood-pressure
  aspirin
- label
  Treat genetic screening as an estimate that may need confirmation
  text
  Cell-free DNA screening, sometimes called NIPT, examines fragments of DNA circulating in the pregnant person's blood, including DNA arising mainly from the placenta. It is a sensitive screen for selected chromosome-number conditions, but it is not a direct diagnostic examination of the fetus. A positive result can be false, and a negative result cannot exclude every genetic or structural condition. SMFM's 2025 guidance, endorsed by ACOG, supports offering common-condition screening with informed counseling and the option to accept or decline testing. Ask what conditions are included and what confirmation is offered after a positive or unclear result. The result should guide a careful discussion, not be treated as an individual prognosis.
  source ids
  genetic-screening
  genetic-detail
- label
  Choose the breadth of genetic information deliberately
  text
  Chromosome conditions are not all tested with equal accuracy. Trisomy means an extra copy of a chromosome; a microdeletion is a missing small chromosome segment. The SMFM guidance treats common trisomy screening, sex-chromosome screening and rare microdeletion panels differently. Sex-chromosome screening is an opt-in choice with counseling; routine general-population microdeletion screening is not recommended. More listed conditions can mean more uncertainty and additional testing, rather than a more complete guarantee. Discuss which information you want for care and preparation, what a laboratory actually validates, and how an uncertain or unexpected result would be handled before the sample is sent.
  source ids
  genetic-screening
  genetic-detail
- label
  Connect an abnormal glucose result to continuing care
  text
  The purpose of identifying gestational diabetes is to help manage glucose and reduce selected pregnancy risks, not merely attach a label. USPSTF's evidence review found treatment benefits for outcomes including large-for-gestational-age birth and shoulder dystocia, when a baby's shoulder becomes difficult to deliver. A care plan may include nutrition support, checking glucose and medication when indicated; the details belong to your clinical team. Ask who will explain results, how monitoring is reviewed and what follow-up is planned after delivery. A diagnosis should lead to understandable support. A normal test also does not settle unrelated symptoms, blood pressure or later concerns.
  source ids
  gdm
id
questions-the-field-is-working-through
role
perspectives
title
Why care approaches can differ
intro
These differences concern how to deliver care or interpret a test. They do not turn folic-acid prevention, urgent assessment or all recommended vaccines into optional matters of opinion.
items
- label
  Discuss a visit schedule that delivers the needed services
  text
  A fixed sequence of frequent office visits and a tailored combination of office and remote care are different ways of arranging services. Michigan researchers working with ACOG describe evidence supporting tailored care for average-risk pregnancies, while high-risk histories may need closer monitoring. The unresolved work includes implementation, access, technology and whether the new models serve different populations equally well. Fewer office visits must still include necessary assessments, tests, prevention and accessible between-visit contact. Ask what each contact accomplishes, what requires an in-person appointment and what would change the schedule. A preference for convenience alone cannot establish that a reduced schedule fits your pregnancy.
  source ids
  prenatal-care
  care-preferences
- label
  Compare glucose-testing pathways by outcomes as well as diagnoses
  text
  The one-step and two-step approaches use different thresholds, so they identify different numbers of people as having gestational diabetes. Hillier and colleagues randomized 23,792 pregnancies in two US health systems: 16.5% were diagnosed in the one-step group versus 8.5% in the two-step group, yet measured main pregnancy and infant outcomes did not significantly differ. More diagnoses did not automatically produce better measured outcomes in that trial. Adherence differed between groups, and the result does not establish that testing or treatment is useless. This is a genuine debate about thresholds, benefit and burden within screening. Ask which local protocol is used and what its result requires, rather than judging its quality by how many diagnoses it finds.
  source ids
  gdm-pathways
- label
  Ask whether an early glucose test is checking a different risk
  text
  USPSTF's 2021 statement found insufficient evidence to judge routine gestational-diabetes screening before 24 weeks; insufficient evidence is different from evidence that it should never occur. In the 2023 TOBOGM trial, Simmons and colleagues studied 802 women with a risk factor and already-diagnosed early gestational diabetes. Immediate treatment modestly reduced a combined infant-outcome measure, without materially changing pregnancy-related hypertension or neonatal lean body mass. That selected treatment trial does not show that every pregnant person benefits from universal early screening. Testing for previously unrecognized diabetes is also a separate clinical question. Ask why an early test is proposed for you and what action would follow its result.
  source ids
  gdm
  early-gdm
- label
  Ask which diagnostic sample best answers a positive genetic screen
  text
  After some positive sex-chromosome screens, clinicians may discuss chorionic villus sampling, which samples placental tissue, or amniocentesis, which samples fluid containing fetal cells. SMFM describes continuing debate because an abnormal chromosome pattern can be present in the placenta without matching the fetus. A placental sample can provide information earlier but sometimes needs further clarification; waiting for a different sample changes the timing of information. The best choice depends on the suspected condition, ultrasound findings and laboratory method. This is a specialist counseling question, not a reason to treat the original blood screen as diagnostic. Ask what each option can confirm and what uncertainty might remain.
  source ids
  genetic-detail
id
care-in-ordinary-life
role
application
title
How to make the care plan fit ordinary life
intro
Care becomes more usable when its medical purpose and practical support are connected.
items
- label
  Read weight gain as a clinical trend rather than a personal verdict
  text
  Pregnancy weight includes changes in maternal tissues and fluid as well as the developing baby; a scale cannot separate those components. CDC's ranges, grounded mainly in National Academies guidance, depend on prepregnancy BMI and differ for singleton and twin pregnancies. BMI is a weight-to-height measure, not a complete account of nutrition or fetal growth. For example, the range for a singleton pregnancy cannot simply be reused for twins. Ask how the team interprets your trend alongside growth assessment, symptoms, intake and medical conditions, and whether nutrition support is needed. Persistent vomiting or difficulty keeping fluids down needs assessment in its own right. A chart does not diagnose the cause of a change or supply a personal meal plan. Imagine someone compares their weight record with a chart and concludes that they must immediately change how much they eat. Before using that chart, the care team needs to know which pregnancy it describes, the starting information and the pattern over time. A singleton chart and a twin chart answer different questions; one isolated number cannot explain a change. The person brings the record, symptoms and any difficulty eating or keeping fluids down, then asks how the team interprets them together. The useful outcome is an explained follow-up plan, including whether nutrition or other assessment is needed—not a self-assigned restriction based on a graph. This invented conversation illustrates how to use guidance as a discussion aid. It does not set a personal weight target, diagnose growth or replace prompt assessment of warning symptoms.
  source ids
  weight
  warning-signs
- label
  Ask how the care setting responds when needs change
  text
  Risk-appropriate care means matching medical needs to the clinicians, equipment and specialist support available. CDC's levels-of-care work explains why someone with complex disease may need a facility with resources beyond routine care. Midwifery and obstetric services can work together, but a professional title or a preferred experience does not establish a setting's emergency capability. Ask who recognizes a new complication, what specialist support is available, and where and how transfer occurs if more intensive care is needed. Maternal and newborn resources both matter. This makes the backup arrangement understandable without assuming that all pregnancies need the same facility or that all settings offer equivalent support.
  source ids
  care-setting
  midwifery
- label
  Bring a previous preterm birth into the current evidence discussion
  text
  Preterm birth means birth before 37 completed weeks. A previous spontaneous preterm birth can change assessment, but an old treatment name is not enough to identify today's options. FDA withdrew 17-OHPC in April 2023 because effectiveness for preventing recurrent spontaneous preterm birth was not established; SMFM's statement, reaffirmed 2025, discourages continued prescribing including compounded versions. Vaginal progesterone for a short cervix and cerclage—a stitch placed in the cervix for selected indications—are separate clinical questions. SMFM also describes uncertainty about progesterone in some other histories. Bring prior records and ask what your current history and cervical assessment support. Do not treat every progesterone formulation, cervical finding or pregnancy type as interchangeable.
  source ids
  preterm
- label
  Tell the team what makes appointments hard to use
  text
  Work hours, transportation, childcare, housing, cost, language and technology access can affect whether a care plan is workable. Peahl's care-delivery work and Howell's maternal-health programs address these as service-design and access concerns. A missed appointment is not an explanation of a person's character or a signal that care is no longer worthwhile. Tell the team what is getting in the way and ask about the appropriate practical help, interpretation, coordinated testing or different contact arrangements. If a result is unclear or a symptom concern is dismissed, ask for a plain explanation and the next available clinical assessment. Safety depends on an understandable response as well as a booked visit.
  source ids
  care-preferences
  equity
  prenatal-care
id
getting-help-between-visits
role
cautions
title
When to get help between appointments
intro
Scheduled care is only one part of the plan. A new warning sign needs a response even after a reassuring test.
items
- label
  Get prompt clinical help for a warning sign
  text
  CDC's list includes severe or persistent headache, vision change, chest pain, trouble breathing, severe belly pain, fever, fainting, bleeding beyond spotting or fluid leakage, and movement stopping or slowing. If one occurs, seek medical care immediately and use emergency services for an emergency; do not wait for a routine visit or an online response. Once you know your baby's usual movement, a reduction matters—CDC does not give one number that is normal for every pregnancy. Discuss any bleeding with the team and seek urgent care for concerning bleeding or accompanying symptoms. These examples are not an exhaustive rule-out list. If something feels wrong or you are unsure, contact a clinician and say you are pregnant.
  source ids
  warning-signs
- label
  Keep follow-up care in place after delivery
  text
  Pregnancy-related problems can arise after birth, so delivery does not end the need for clinical follow-up. CDC's HEAR HER guidance extends into the year after pregnancy and asks patients to tell receiving clinicians about a recent pregnancy. Keep the discharge instructions, urgent contact and handoff for ongoing conditions and medicines together. For instance, a glucose or blood-pressure concern may require follow-up beyond the birth admission; ask which clinician will review it. Stuebe's fourth trimester work treats recovery and support as a continuing care period. Postpartum means after birth, and care in that period concerns the parent's health as well as the infant's.
  source ids
  warning-signs
  panel-9
  equity
- label
  Use this reading alongside your own prenatal care
  text
  This is a reading companion, not prenatal care, not a birth plan, and not an intimacy guide. Bleeding, severe headache, vision change, chest pain, or a later drop in fetal movement needs urgent clinical care. Do not start or stop medicines from this text. This page does not treat one pregnancy. Named sources. Honest paraphrase of the finding. Not medical, legal, or financial advice.
  source ids
  warning-signs
  medicines
id
keeping-the-plan-clear
role
application
title
What to keep with your care record
intro
A few useful records help the team review changes without relying on memory. They support the care relationship; they are not a home diagnosis system.
items
- label
  Know who will explain results and arrange follow-up
  text
  Record who ordered each test and who will explain it, especially if more than one practice is involved. Ask when results are expected and whom to contact if that date passes. A portal notification can show that a result exists without showing that its meaning or next action has been discussed. Bring unanswered questions to the next contact and ask how missed visits are rescheduled.
  source ids
  prenatal-care
  gdm
- label
  Keep the agreed supplement plan with the medicine list
  text
  Write the product, ingredient amount and frequency, then add any change the clinical team recommends. This helps avoid accidental overlap when someone suggests another prenatal product. Keep the purpose clear: folic acid lowers the risk of specific early structural defects; it does not treat a detected defect. Review changes rather than interpreting a different bottle as a stronger prevention plan.
  source ids
  folic-label
  folic-acid
  medicines
- label
  Keep vaccine dates as well as names
  text
  Record the administered product and date, and bring that record when a different clinic gives care. A list saying flu or RSV does not show whether the intended seasonal or maternal dose was given. Pregnancy week, season and previous receipt can change the answer. Ask the prenatal team to identify what is complete and what still needs a scheduled discussion.
  source ids
  vaccines
  acog-vaccines
- label
  Keep urgent instructions where a support person can find them
  text
  Save the after-hours contact and intended care location alongside the warning-sign reminder. A support person can help describe the change or arrange transport, but their reassurance cannot replace an assessment. Ask what to do if the urgent number is unanswered. For an emergency, use emergency services rather than waiting indefinitely for a routine callback.
  source ids
  warning-signs
- label
  Keep changes and questions visible between appointments
  text
  Note a new symptom, medicine change or difficulty following the plan so it can be discussed accurately. Record what the team told you and what remains unresolved, rather than collecting an unstructured pile of reassuring screenshots. Routine questions can go through the agreed channel; warning signs need the urgent route. The distinction helps a care team give the right response at the right time.
  source ids
  medicines
  prenatal-care
  warning-signs
id
checking-common-claims
role
findings
title
Check the claim before acting on it
intro
These answers distinguish evidence from popular reassurance. The verdict concerns the statement shown, not an individual pregnancy.
items
- label
  Begin the care relationship while you feel well
  text
  Claim: Early prenatal care is the field's starting step. Verdict: established. Early contact begins assessment, prevention and planning; the actual visit schedule can be tailored.
  source ids
  who-care
  prenatal-care
- label
  Use folic acid for its specific prevention benefit
  text
  Claim: Folic acid is recommended to prevent neural-tube defects for people who could become pregnant. Verdict: established. The standard recommendation is for average-risk people; higher-risk histories need separate clinical review.
  source ids
  folic-acid
  folic-clinical
- label
  Use a product-specific vaccine recommendation
  text
  Claim: Vaccines are never used in pregnancy. Verdict: not what the research found. Guidance recommends specific products with pregnancy-specific timing.
  source ids
  vaccines
  acog-vaccines
- label
  Use prevention guidance instead of an anecdotal alcohol allowance
  text
  Claim: A little alcohol in pregnancy has a known safe amount. Verdict: not what the research found. CDC identifies no known safe allowance; past exposure cannot establish an individual prognosis.
  source ids
  alcohol
- label
  Let symptoms trigger assessment rather than calendar waiting
  text
  Claim: Severe headache with vision change can wait for the next scheduled visit. Verdict: not what the research found. Those symptoms need urgent clinical assessment.
  source ids
  warning-signs
- label
  Know the role of ordinary glucose screening
  text
  Claim: Gestational-diabetes screening is ordinary prenatal care in most US pathways. Verdict: established. USPSTF supports screening at 24 weeks or later; a testing-pathway debate does not remove that recommendation.
  source ids
  gdm
  gdm-pathways
- label
  Reserve aspirin for a clinical prevention decision
  text
  Claim: Low-dose aspirin is a general pregnancy vitamin. Verdict: not what the research found. It is a medicine prescribed for selected preeclampsia-risk profiles.
  source ids
  aspirin
id
one-useful-next-step
role
next_steps
title
Make the next prenatal contact useful
intro
One move: contact the prenatal service, or use your existing team, to confirm the care plan and how you will receive results. Bring the relevant records; use urgent care immediately if a warning sign is present.
items
- label
  Bring the details that let the team answer your real questions
  text
  Prepare a current medicine and supplement list with doses, product labels, vaccination dates and relevant previous pregnancy records. Ask: What needs attention before my next appointment, which tests come next, and who explains the results? Include the folic-acid question and any access difficulty. This gives the team concrete information to review instead of expecting you to know which history matters.
  source ids
  medicines
  folic-label
  prenatal-care
- label
  Try a label-and-record check before the appointment
  text
  Read the folic-acid amount on your actual product and note other vitamins or herbal ingredients you use. Then check your vaccination record for names and dates. Bring uncertainties to the team rather than adding products or repeating doses yourself. The goal is one understandable prevention plan with individual exceptions reviewed by a clinician.
  source ids
  folic-label
  medicines
  vaccines
- label
  Try saving the follow-up and urgent routes together
  text
  Ask which number handles routine questions, which route is available after hours and where urgent symptoms should be assessed. Save the instructions where you and a support person can find them. Ask when to expect a test result and what to do if nobody explains it. The plan should cover both ordinary follow-up and unexpected change, including the handoff after delivery.
  source ids
  prenatal-care
  warning-signs

related

nutrition
sleep
fitness

sources

id
prenatal-care
title
Revolutionizing prenatal care: new guidelines to transform 100-year model
url
https://ihpi.umich.edu/news-events/news/revolutionizing-prenatal-care-new-guidelines-transform-100-year-model
kind
professional
accessed at
2026-10-01
supports
Opened Michigan's April 2025 account of its work with ACOG: early risk assessment; individualized services, visit schedules, telemedicine and social support.
limitations
An institutional explanation from the researchers involved; the full ACOG Clinical Consensus was unavailable for review. It does not establish one visit count for every pregnancy.
id
care-preferences
title
Right-sizing prenatal care
url
https://ihpi.umich.edu/news-events/news/right-sizing-prenatal-care
kind
professional
accessed at
2026-10-01
supports
Peahl's public explanation of a 300-person postpartum preference study, between-visit contact and practical access barriers.
limitations
2020 institutional account; preferences do not demonstrate clinical safety or determine any patient's schedule.
id
who-care
title
WHO recommendations on antenatal care for a positive pregnancy experience
url
https://www.who.int/publications/i/item/9789241549912
kind
guideline
accessed at
2026-10-01
supports
Opened overview: assessment, prevention, nutrition, symptoms and person-centred antenatal care; WHO lists subsequent targeted updates.
limitations
Publication overview and update links read, not all 196 pages. Global guidance requires local adaptation.
id
folic-acid
title
Folic Acid Supplementation to Prevent Neural Tube Defects: Preventive Medication
url
https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/folic-acid-for-the-prevention-of-neural-tube-defects-preventive-medication
kind
guideline
accessed at
2026-10-01
supports
2023 USPSTF average-risk recommendation, 400–800 mcg daily, preconception timing, early neural-tube closure, exclusions for very-high-risk histories.
limitations
Prevention reduces risk; does not guarantee outcome or treat an established defect; higher-risk dosing requires individual care.
id
folic-label
title
Folic Acid: Sources and Recommended Intake
url
https://www.cdc.gov/folic-acid/about/intake-and-sources.html
kind
official
accessed at
2026-10-01
supports
Opened CDC intake guidance and supplement/food distinction; actual folic-acid amount matters.
limitations
General public guidance, not personalized total nutrient requirements or a product endorsement.
id
folic-clinical
title
Folic Acid: Facts for Clinicians
url
https://www.cdc.gov/folic-acid/hcp/clinical-overview/index.html
kind
official
accessed at
2026-10-01
supports
Opened CDC clinical summary of folic-acid prevention and research on folate forms.
limitations
Does not establish that an arbitrary prenatal brand or higher dose is necessary.
id
mthfr
title
MTHFR Gene Variant and Folic Acid Facts
url
https://www.cdc.gov/folic-acid/data-research/mthfr/index.html
kind
official
accessed at
2026-10-01
supports
Opened CDC explanation that common MTHFR variants do not prevent folic-acid processing and folic acid has neural-tube-prevention evidence.
limitations
Common variants are different from rare metabolic disorders; not a personalized genetics assessment.
id
vaccines
title
Guidelines for Vaccinating Pregnant Women
url
https://www.cdc.gov/vaccines-pregnancy/hcp/vaccination-guidelines/index.html
kind
guideline
accessed at
2026-10-01
supports
Opened product/timing table and sections: Tdap each pregnancy, seasonal IIV/RIV, maternal Abrysvo weeks 32–36 and seasonal eligibility, prior maternal RSV receipt.
limitations
Page's COVID table is incomplete and linked to later guidance. Maternal RSV rules differ from other adult RSV products; local seasonality matters.
id
acog-vaccines
title
ACOG 2026 Maternal Immunization Schedule
url
https://cdn.ymaws.com/npwh.org/resource/resmgr/resources/ACOG_2026_Maternal_Immunizat.pdf
kind
guideline
accessed at
2026-10-01
supports
Opened ACOG schedule hosted by endorsing NPWH; pages 1–2 text: Tdap, COVID-19, influenza and RSV recommendations and timing.
limitations
An ACOG schedule hosted by the endorsing organization NPWH, rather than a personal prescription.
id
covid-current
title
Interim Clinical Considerations for Use of COVID-19 Vaccines in the United States
url
https://www.cdc.gov/covid/hcp/vaccine-considerations/index.html
kind
guideline
accessed at
2026-10-01
supports
Opened September 23, 2026 clinical page: 2026–2027 adult recommendation, current regulatory information and individualized benefits/risks discussion.
limitations
Landing-page summary read; no brand, dose or regulatory eligibility inferred. A stale 'last updated 2025' subheading conflicts with 2026 page metadata.
id
covid-pregnancy
title
COVID-19 Vaccination for Women Who Are Pregnant or Breastfeeding
url
https://www.cdc.gov/covid/vaccines/pregnant-or-breastfeeding.html
kind
official
accessed at
2026-10-01
supports
Opened pregnancy risk/safety explanation and notice directing readers to newer 2026–2027 guidance.
limitations
Body still describes 2025–2026 decision language; used for pregnancy risk and update warning, not current schedule.
id
alcohol
title
About Alcohol Use During Pregnancy
url
https://www.cdc.gov/alcohol-pregnancy/about/index.html
kind
official
accessed at
2026-10-01
supports
Opened current CDC page: no known safe amount/time/type, variable outcomes, prevention after pregnancy recognition and continued checkups.
limitations
Cannot predict an individual outcome from a reported exposure.
id
medicines
title
Medicine and Pregnancy: An Overview
url
https://www.cdc.gov/medicine-and-pregnancy/about/
kind
official
accessed at
2026-10-01
supports
Opened CDC advice to review prescriptions, OTC medicines, herbal/dietary supplements and vitamins before starting/stopping; untreated illness can also harm.
limitations
Many medicines lack adequate pregnancy safety evidence; no medicine-specific approval inferred.
id
warning-signs
title
Urgent Maternal Warning Signs and Symptoms
url
https://www.cdc.gov/hearher/maternal-warning-signs/index.html
kind
official
accessed at
2026-10-01
supports
Opened CDC warning list, immediate-care direction, pregnancy/recent-pregnancy disclosure, movement change rather than universal count and one-year window.
limitations
The list is not exhaustive and cannot diagnose or rule out danger. CDC specifies bleeding beyond spotting; any bleeding should still be discussed with the care team.
id
gdm
title
Gestational Diabetes: Screening
url
https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/gestational-diabetes-screening
kind
guideline
accessed at
2026-10-01
supports
Opened USPSTF 2021 summary, implementation and evidence: asymptomatic screening at 24 weeks or later, often 24–28; one-/two-step pathways; earlier evidence insufficient.
limitations
Excludes previously diagnosed type 1/2 diabetes; early insufficiency is a dated evidence assessment, not a prohibition and not evaluation of symptoms.
id
gdm-pathways
title
A Pragmatic Randomized Clinical Trial of Gestational Diabetes Screening
url
https://pmc.ncbi.nlm.nih.gov/articles/PMC9041326/
kind
study
accessed at
2026-10-01
supports
Opened Hillier et al. 2021 full author manuscript: 23,792 randomized pregnancies, diagnosis 16.5% vs 8.5%, no significant main outcome differences; adherence 66% vs 92%.
limitations
Two US integrated systems; nonadherence and threshold differences limit extrapolation. Compares two screened groups, not screening versus no screening.
id
early-gdm
title
Treatment of Gestational Diabetes Mellitus Diagnosed Early in Pregnancy
url
https://pubmed.ncbi.nlm.nih.gov/37144983/
kind
study
accessed at
2026-10-01
supports
Opened Simmons et al. 2023 primary-trial abstract: 802 selected women with risk factor and early GDM; neonatal composite 24.9% vs 30.5%; no material hypertension/lean-body-mass differences.
limitations
Abstract only; treatment trial in an already selected/diagnosed group, not universal early-screening trial; composite not every component separately.
id
blood-pressure
title
High Blood Pressure During Pregnancy
url
https://www.cdc.gov/high-blood-pressure/about/high-blood-pressure-during-pregnancy.html
kind
official
accessed at
2026-10-01
supports
Opened definitions and prenatal/postpartum blood-pressure significance, preeclampsia and related clinical features.
limitations
General education; no home diagnostic threshold or treatment algorithm supplied.
id
aspirin
title
Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality: Preventive Medication
url
https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/low-dose-aspirin-use-for-the-prevention-of-morbidity-and-mortality-from-preeclampsia-preventive-medication
kind
guideline
accessed at
2026-10-01
supports
Opened USPSTF 2021 recommendation/risk factors and evidence: 81 mg/day after 12 weeks for selected high-risk pregnancies; pooled preeclampsia RR 0.85.
limitations
Clinician prescribing, not universal supplement advice. Absolute benefit varies with baseline risk; prevention does not rule out later symptoms.
id
genetic-screening
title
Society for Maternal-Fetal Medicine Consult Series #74: Cell-free DNA screening for aneuploidies: Updated guidance
url
https://publications.smfm.org/publications/620-society-for-maternal-fetal-medicine-consult-series-74cell/
kind
guideline
accessed at
2026-10-01
supports
Opened SMFM 2025 summary endorsed by ACOG: common aneuploidy screening, informed accept/decline choice, opt-in sex-chromosome screening and no routine microdeletion screening.
limitations
Screening does not diagnose; recommendation varies by target condition, pregnancy type and test method.
id
genetic-detail
title
SMFM Consult Series #74 full guidance
url
https://assets.noviams.com/novi-file-uploads/smfm/Publications_and_Guidelines/Consults/SMFM_Consult_Series_74_Cell_free_DNA_screening_for_aneuploidies_Updated_guidance.pdf
kind
guideline
accessed at
2026-10-01
supports
Opened PDF relevant sections on placental DNA, false results, pretest counseling, confirmatory testing and CVS/amniocentesis tradeoffs for sex-chromosome results.
limitations
Relevant sections read, not every reference or full 25 pages line by line. Rare conditions have limited confirmation data; not a personal test decision.
id
weight
title
Weight Gain During Pregnancy
url
https://www.cdc.gov/maternal-infant-health/pregnancy-weight/index.html
kind
official
accessed at
2026-10-01
supports
Explains BMI-specific ranges for singleton and twin pregnancies and the role of discussion with the care team.
limitations
Population ranges are not individual diagnosis, diet plan or moral judgment. No target range assigned to reader.
id
care-setting
title
CDC Levels of Care Assessment Tool (CDC LOCATe)
url
https://www.cdc.gov/maternal-infant-health/php/cdc-locate/
kind
official
accessed at
2026-10-01
supports
Opened risk-appropriate facility care, specialist/equipment availability and variable state definitions; based on ACOG/SMFM/AAP guidance.
limitations
Public-health tool, not certification of any specific hospital or home/birth-centre setting.
id
preterm
title
SMFM Statement: Response to FDA withdrawal of 17-alpha hydroxyprogesterone caproate
url
https://publications.smfm.org/publications/467-society-for-maternal-fetal-medicine-statement-response-to/
kind
guideline
accessed at
2026-10-01
supports
Opened 2023 statement reaffirmed 2025: April 5, 2023 withdrawal, discourage compounded 17-OHPC; distinct short-cervix progesterone/cerclage indications and shared-decision uncertainty remain.
limitations
Does not establish a prevention regimen for all prior preterm births or all pregnancy types.
id
midwifery
title
Midwifery — University of Maryland School of Medicine
url
https://www.medschool.umaryland.edu/ob/divisions--centers/midwifery/
kind
professional
accessed at
2026-10-01
supports
Opened official patient explanation of CNM/physician teamwork, prenatal care, postpartum and nutrition education; Fahey named.
limitations
One service model; not proof all midwifery or obstetric settings have equivalent resources.
id
equity
title
New center will tackle racial disparities in maternal health
url
https://www.pennmedicine.org/news/new-center-will-tackle-racial-disparities-in-maternal-health
kind
professional
accessed at
2026-10-01
supports
Opened Howell-led program account: care access, treatment standardization and postpartum coordination.
limitations
Institutional description of programs/research plans; does not prove every proposed program improves every outcome.
id
question-first-visit
title
Early pregnancy — public discussion
url
https://www.reddit.com/r/pregnant/comments/1vqomr6/early_pregnancy/
kind
question_signal
accessed at
2026-10-01
supports
Opened reader's question about an appointment a month away, folic acid and medicines; used to choose reader situations.
limitations
Anonymous self-report and comments are not factual authority, clinical advice or representative prevalence.
id
question-weight
title
Any experiences with not gaining a lot of weight during twin pregnancy?
url
https://www.reddit.com/r/parentsofmultiples/comments/1tdisyt/any_experiences_with_not_gaining_a_lot_of_weight/
kind
question_signal
accessed at
2026-10-01
supports
Opened worry about generic twin weight-gain ranges; informs nonjudgmental explanation.
limitations
Anecdotes cannot establish a safe weight target or fetal growth assessment.
id
panel-1
title
Catherine Y. Spong — official role and public contribution
url
https://utswmed.org/doctors/catherine-spong/
kind
professional
accessed at
2026-10-01
supports
MD; maternal-fetal medicine specialist and UT Southwestern obstetrics/gynecology professor; Official public biography explains fetal-complication research and inclusion of pregnant people in studies.
limitations
Role/publication biography does not establish every treatment claim or offer individual prenatal care.
id
panel-2
title
Mary E. D'Alton — official role and public contribution
url
https://www.obgyn.columbia.edu/profile/mary-e-dalton-md
kind
professional
accessed at
2026-10-01
supports
MD; maternal-fetal medicine specialist, Columbia obstetrics/gynecology professor; Official patient biography describes multidisciplinary care and Safe Motherhood work; clinical textbook/editorial contributions are public teaching.
limitations
Current page describes former chair role historically; no current chair claim. Facility guidance, not biography, supports the reader's care-setting finding.
id
panel-3
title
Uma M. Reddy — official role and public contribution
url
https://medicine.yale.edu/profile/uma-reddy/
kind
professional
accessed at
2026-10-01
supports
MD, MPH; board-certified maternal-fetal medicine specialist; Yale obstetrics/gynecology professor; Public patient explanation and official research biography cover high-risk pregnancy, stillbirth and preterm-birth studies.
limitations
Population research cannot predict one pregnancy's outcome. Yale 2026 return verified; no old Columbia role treated as current.
id
panel-4
title
Dwight J. Rouse — official role and public contribution
url
https://www.brownhealth.org/providers/dwight-j-rouse-md
kind
professional
accessed at
2026-10-01
supports
MD; maternal-fetal medicine and obstetrics/gynecology physician listed by Brown University Health; Brown's public CV documents professional teaching awards, guideline review and obstetric trial publications.
limitations
CV is dated 2019; used for historical teaching/contributions, not current professor titles. Current clinical specialties verified separately.
id
panel-5
title
George R. Saade — official role and public contribution
url
https://www.odu.edu/directory/profiles/george-saade
kind
professional
accessed at
2026-10-01
supports
MD; board-certified obstetrics/gynecology and maternal-fetal medicine physician; Old Dominion professor; Official biography documents maternal-fetal society education/advocacy, mentorship and perinatal editorial work.
limitations
Professional leadership is not individual prognosis; no article claim rests solely on his role.
id
panel-6
title
Vincenzo Berghella — official role and public contribution
url
https://profiles.jefferson.edu/display/32938
kind
professional
accessed at
2026-10-01
supports
MD; Jefferson faculty physician in obstetrics/gynecology; maternal-fetal medicine field contributor; Public institutional publication record includes evidence reviews and obstetric research/editorial teaching.
limitations
Institutional publication list warns of automated attribution errors; verified selected topic contributions only. Treatment statement supplies current guidance.
id
panel-7
title
Jeanne S. Sheffield — official role and public contribution
url
https://profiles.hopkinsmedicine.org/provider/jeanne-s-sheffield/2700629
kind
professional
accessed at
2026-10-01
supports
MD; Johns Hopkins professor of gynecology/obstetrics and maternal-fetal medicine division director; Official patient biography explicitly explains infectious-disease and immunization expertise.
limitations
Physician biography is not vaccine-schedule evidence; current CDC/ACOG documents determine products/timing.
id
panel-8
title
Laura E. Riley — official role and public contribution
url
https://weillcornell.org/laura-e-riley-md
kind
professional
accessed at
2026-10-01
supports
MD; maternal-fetal medicine specialist at Weill Cornell Medicine; Public biography and institutional interviews explain high-risk pregnancy and infectious-disease work.
limitations
Leadership and public reach do not replace vaccine safety data or product-specific recommendations.
id
panel-9
title
Alison M. Stuebe — official role and public contribution
url
https://news.unchealthcare.org/2020/10/stuebe-named-maternal-fetal-medicine-division-director/
kind
professional
accessed at
2026-10-01
supports
MD, MSc; board-certified maternal-fetal medicine subspecialist, UNC researcher; Official public account describes fourth Trimester work and a patient-safety learning lab to redesign postnatal care.
limitations
2020 role announcement verifies training/research contribution, not all current administrative titles; lactation outcomes are not generalized to all prenatal questions.
id
panel-10
title
Aaron B. Caughey — official role and public contribution
url
https://www.ohsu.edu/people/aaron-b-caughey-md-phd
kind
professional
accessed at
2026-10-01
supports
MD, PhD; OHSU obstetrics/gynecology professor; training in obstetric ultrasound; Public faculty/provider pages and listed research/policy teaching explain obstetric evidence and decision-making.
limitations
No claim that this profile establishes a universal delivery date or personal screening plan.
id
panel-11
title
Alex F. Peahl — official role and public contribution
url
https://medschool.umich.edu/profile/5667/alex-f-peahl
kind
professional
accessed at
2026-10-01
supports
MD, MSc; University of Michigan assistant professor of obstetrics/gynecology; Opened public interviews about tailored prenatal care and official clinical/research profile.
limitations
Institutional account is evidence translation; reduced visit schedules for average-risk populations cannot be assigned to all pregnancies.
id
panel-12
title
Mary E. Norton — official role and public contribution
url
https://profiles.ucsf.edu/mary.norton
kind
professional
accessed at
2026-10-01
supports
MD; UCSF perinatologist and clinical geneticist; Official public biography and research list address patient decisions, ultrasound and prenatal genetic testing.
limitations
Genetic-test expertise does not make every expanded commercial panel validated or guarantee a healthy infant.
id
panel-13
title
Wanda K. Nicholson — official role and public contribution
url
https://publichealth.gwu.edu/departments/prevention-and-community-health/wanda-nicholson
kind
professional
accessed at
2026-10-01
supports
MD, MPH, MBA; obstetrician/gynecologist and epidemiologist; GW professor; Official biography describes perinatal diabetes/CVD research and public professional teaching in translating evidence into practice.
limitations
USPSTF recommendations are collective evidence assessments, not her personal advice; population risk does not prescribe treatment to a reader.
id
panel-14
title
Jenifer O. Fahey — official role and public contribution
url
https://www.umms.org/find-a-doctor/profiles/jenifer-fahey-1538197017
kind
professional
accessed at
2026-10-01
supports
CNM, MPH; certified nurse-midwife and University of Maryland faculty clinician; Official public patient-service pages explain prenatal/postpartum care; opened Maryland public workgroup minutes record hospital-based midwifery teaching.
limitations
Hospital-based service examples cannot establish the capability of every setting or credentials of all people called midwives.
id
panel-15
title
Elizabeth A. Howell — official role and public contribution
url
https://www.pennmedicine.org/news/new-center-will-tackle-racial-disparities-in-maternal-health
kind
professional
accessed at
2026-10-01
supports
MD, MPP; Penn obstetrics/gynecology physician-researcher and maternal-health equity center leader; Opened public institutional explanations of maternal-health equity and continued care after pregnancy.
limitations
A described initiative or planned study is not evidence that every intervention works; no personal risk inferred from group disparities.
id
rouse-teaching
title
Dwight J. Rouse curriculum vitae (September 2019)
url
https://vivo.brown.edu/docs/d/drouse_cv.pdf?dt=515610267
kind
professional
accessed at
2026-10-01
supports
Opened historical credentials, teaching awards and guideline/evidence review contributions.
limitations
Historical CV; no current administrative position inferred.
id
fahey-teaching
title
Maryland Midwives Workgroup Meeting 4 minutes (December 3, 2012)
url
https://health.maryland.gov/midwives/Documents/MidwivesWorkgroupMeeting4-Minutes12-3-12.pdf
kind
official
accessed at
2026-10-01
supports
Opened public minutes recording Fahey's hospital-based midwifery presentation.
limitations
Historical professional public education, not current regulation or clinical outcome evidence.

professional panel

name
Catherine Y. Spong
credential
MD; maternal-fetal medicine specialist and UT Southwestern obstetrics/gynecology professor
official url
https://utswmed.org/doctors/catherine-spong/
public usefulness
Official public biography explains fetal-complication research and inclusion of pregnant people in studies.
contribution
Connects prenatal evidence literacy to the populations actually studied, rather than assuming every pregnancy is represented.
boundary
Role/publication biography does not establish every treatment claim or offer individual prenatal care.
reviewed at
2026-10-01
name
Mary E. D'Alton
credential
MD; maternal-fetal medicine specialist, Columbia obstetrics/gynecology professor
official url
https://www.obgyn.columbia.edu/profile/mary-e-dalton-md
public usefulness
Official patient biography describes multidisciplinary care and Safe Motherhood work; clinical textbook/editorial contributions are public teaching.
contribution
Explains why staff, specialist access and referral capability matter for high-risk care.
boundary
Current page describes former chair role historically; no current chair claim. Facility guidance, not biography, supports the reader's care-setting finding.
reviewed at
2026-10-01
name
Uma M. Reddy
credential
MD, MPH; board-certified maternal-fetal medicine specialist; Yale obstetrics/gynecology professor
official url
https://medicine.yale.edu/profile/uma-reddy/
public usefulness
Public patient explanation and official research biography cover high-risk pregnancy, stillbirth and preterm-birth studies.
contribution
Shows how pregnancy history changes monitoring and why a screening result cannot replace continuing care.
boundary
Population research cannot predict one pregnancy's outcome. Yale 2026 return verified; no old Columbia role treated as current.
reviewed at
2026-10-01
name
Dwight J. Rouse
credential
MD; maternal-fetal medicine and obstetrics/gynecology physician listed by Brown University Health
official url
https://www.brownhealth.org/providers/dwight-j-rouse-md
public usefulness
Brown's public CV documents professional teaching awards, guideline review and obstetric trial publications.
contribution
Provides an evidence-method perspective: clinical trial populations/comparators matter more than a familiar protocol.
boundary
CV is dated 2019; used for historical teaching/contributions, not current professor titles. Current clinical specialties verified separately.
reviewed at
2026-10-01
name
George R. Saade
credential
MD; board-certified obstetrics/gynecology and maternal-fetal medicine physician; Old Dominion professor
official url
https://www.odu.edu/directory/profiles/george-saade
public usefulness
Official biography documents maternal-fetal society education/advocacy, mentorship and perinatal editorial work.
contribution
Helps contextualize high-risk pregnancy trials and how evidence becomes professional guidance.
boundary
Professional leadership is not individual prognosis; no article claim rests solely on his role.
reviewed at
2026-10-01
name
Vincenzo Berghella
credential
MD; Jefferson faculty physician in obstetrics/gynecology; maternal-fetal medicine field contributor
official url
https://profiles.jefferson.edu/display/32938
public usefulness
Public institutional publication record includes evidence reviews and obstetric research/editorial teaching.
contribution
Preterm prevention and evidence synthesis support explaining why different progesterone formulations/indications are not interchangeable.
boundary
Institutional publication list warns of automated attribution errors; verified selected topic contributions only. Treatment statement supplies current guidance.
reviewed at
2026-10-01
name
Jeanne S. Sheffield
credential
MD; Johns Hopkins professor of gynecology/obstetrics and maternal-fetal medicine division director
official url
https://profiles.hopkinsmedicine.org/provider/jeanne-s-sheffield/2700629
public usefulness
Official patient biography explicitly explains infectious-disease and immunization expertise.
contribution
Adds pregnancy-specific infection and vaccine interpretation rather than a blanket vaccine rule.
boundary
Physician biography is not vaccine-schedule evidence; current CDC/ACOG documents determine products/timing.
reviewed at
2026-10-01
name
Laura E. Riley
credential
MD; maternal-fetal medicine specialist at Weill Cornell Medicine
official url
https://weillcornell.org/laura-e-riley-md
public usefulness
Public biography and institutional interviews explain high-risk pregnancy and infectious-disease work.
contribution
Connects infection prevention to clinical pregnancy care and public explanation of immunization questions.
boundary
Leadership and public reach do not replace vaccine safety data or product-specific recommendations.
reviewed at
2026-10-01
name
Alison M. Stuebe
credential
MD, MSc; board-certified maternal-fetal medicine subspecialist, UNC researcher
official url
https://news.unchealthcare.org/2020/10/stuebe-named-maternal-fetal-medicine-division-director/
public usefulness
Official public account describes fourth Trimester work and a patient-safety learning lab to redesign postnatal care.
contribution
Preserves the handoff from pregnancy to recovery, ongoing conditions and postpartum support.
boundary
2020 role announcement verifies training/research contribution, not all current administrative titles; lactation outcomes are not generalized to all prenatal questions.
reviewed at
2026-10-01
name
Aaron B. Caughey
credential
MD, PhD; OHSU obstetrics/gynecology professor; training in obstetric ultrasound
official url
https://www.ohsu.edu/people/aaron-b-caughey-md-phd
public usefulness
Public faculty/provider pages and listed research/policy teaching explain obstetric evidence and decision-making.
contribution
Adds a clinical-research/policy perspective on prenatal screening choices and outcome comparisons.
boundary
No claim that this profile establishes a universal delivery date or personal screening plan.
reviewed at
2026-10-01
name
Alex F. Peahl
credential
MD, MSc; University of Michigan assistant professor of obstetrics/gynecology
official url
https://medschool.umich.edu/profile/5667/alex-f-peahl
public usefulness
Opened public interviews about tailored prenatal care and official clinical/research profile.
contribution
MiPATH research examines how prenatal services can respond to medical risk and practical barriers to care.
boundary
Institutional account is evidence translation; reduced visit schedules for average-risk populations cannot be assigned to all pregnancies.
reviewed at
2026-10-01
name
Mary E. Norton
credential
MD; UCSF perinatologist and clinical geneticist
official url
https://profiles.ucsf.edu/mary.norton
public usefulness
Official public biography and research list address patient decisions, ultrasound and prenatal genetic testing.
contribution
Clarifies the distinct jobs of a screening estimate and diagnostic confirmation.
boundary
Genetic-test expertise does not make every expanded commercial panel validated or guarantee a healthy infant.
reviewed at
2026-10-01
name
Wanda K. Nicholson
credential
MD, MPH, MBA; obstetrician/gynecologist and epidemiologist; GW professor
official url
https://publichealth.gwu.edu/departments/prevention-and-community-health/wanda-nicholson
public usefulness
Official biography describes perinatal diabetes/CVD research and public professional teaching in translating evidence into practice.
contribution
Explains how to evaluate prevention evidence and maintain care from pregnancy through the postpartum period.
boundary
USPSTF recommendations are collective evidence assessments, not her personal advice; population risk does not prescribe treatment to a reader.
reviewed at
2026-10-01
name
Jenifer O. Fahey
credential
CNM, MPH; certified nurse-midwife and University of Maryland faculty clinician
official url
https://www.umms.org/find-a-doctor/profiles/jenifer-fahey-1538197017
public usefulness
Official public patient-service pages explain prenatal/postpartum care; opened Maryland public workgroup minutes record hospital-based midwifery teaching.
contribution
Explains collaborative midwifery care, informed choices and nutrition education.
boundary
Hospital-based service examples cannot establish the capability of every setting or credentials of all people called midwives.
reviewed at
2026-10-01
name
Elizabeth A. Howell
credential
MD, MPP; Penn obstetrics/gynecology physician-researcher and maternal-health equity center leader
official url
https://www.pennmedicine.org/news/new-center-will-tackle-racial-disparities-in-maternal-health
public usefulness
Opened public institutional explanations of maternal-health equity and continued care after pregnancy.
contribution
Her work examines how access, communication and coordination among services affect maternal care.
boundary
A described initiative or planned study is not evidence that every intervention works; no personal risk inferred from group disparities.
reviewed at
2026-10-01

Download original public profile Download complete article

End of Pregnancy / prenatal